CUMULATIVE
SUPPLEMENT 4
APRIL 2003

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2003


rch
HYMAN, PHELPS
&MCNAMARA, P.C.
WASHINGTON, DC
DEMCO

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23RD EDITION

Cumulative Supplement 4

April 2003

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

23rd EDITION

CUMULATIVE SUPPLEMENT 4
April 2003

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 23rd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
SYNTEX (USA) INC LLC (SYNTEX USA INC)	ROCHE PALO ALTO LLC (ROCHE PALO)
LEK SERVICES INC (LEK SVCS)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO (LEK LJUBLJANA)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK PHARMACEUTICAL AND CHEMICAL DD (LEK PHARM)	LEK PHARMACEUTICALS DD (LEK PHARM DD)

1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL 23RD ANNUAL EDITION

The *Approved Drug Products with Therapeutic Equivalence Evaluations 23rd annual edition*, page 3-265 omitted the 3 character Therapeutic Equivalence (TE) Codes for Nitroglycerin, Film, Extended Release; Transdermal products. The correct codes are listed below by product name, applicant holder, TE code, strength, NDA number, and product number.

PRODUCT NAME	APPLICANT	TE CODE	STRENGTH	NDA	PRODUCT
MINITRAN	3M	AB1	0.1MG/HR	N89771	001
MINITRAN	3M	AB1	0.2MG/HR	N89772	001
MINITRAN	3M	AB1	0.4MG/HR	N89773	001
MINITRAN	3M	AB1	0.6MG/HR	N89774	001
NITRO-DUR	KEY PHARMS	AB1	0.1MG/HR	N20145	001
NITRO-DUR	KEY PHARMS	AB1	0.2MG/HR	N20145	002
NITRO-DUR	KEY PHARMS	AB1	0.4MG/HR	N20145	004
NITRO-DUR	KEY PHARMS	AB1	0.6MG/HR	N20145	005
NITROGLYCERIN	HERCON LABS	AB2	0.2MG/HR	N89884	001
NITROGLYCERIN	HERCON LABS	AB2	0.4MG/HR	N89885	001
NITROGLYCERIN	HERCON LABS	AB2	0.6MG/HR	N89886	001
NITROGLYCERIN	MYLAN	AB2	0.1MG/HR	N75033	001
NITROGLYCERIN	MYLAN	AB2	0.2MG/HR	N74609	001
NITROGLYCERIN	MYLAN	AB2	0.4MG/HR	N74607	001

1.4 AVAILABILITY OF THE EDITION

The 23rd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is $108.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm

The Internet version of the monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 23rd annual edition of the 2002 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder.orange/23bookpub.pdf

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.
The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.htm

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2002) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2002	JUN 2003	SEP 2003	DEC 2003
DRUG PRODUCTS LISTED	10465			
SINGLE SOURCE	2420 (23.1%)			
MULTISOURCE	7939 (75.9%)			
THERAPEUTICALLY EQUIVALENT	7659 (73.2%)			
NOT THERAPEUTICALLY EQUIVALENT	280 (2.7%)			
EXCEPTIONS[1]	106 (1.0%)			
NEW MOLECULAR ENTITIES APPROVED	6			
NUMBER OF APPLICANTS	598			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

			ACETAMINOPHEN; BUTALBITAL; CAFFEINE						
			SOLUTION; ORAL						
			ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE						
		+	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	N40387 001	JAN 31, 2003	JAN	NEWA
			TABLET; ORAL						
			FIORICET						
>D>	AB	+	NOVARTIS	325MG;50MG;40MG	N88616 001	NOV 09, 1984	APR	CAHN
>A>	AB	+	WATSON PHARMS	325MG;50MG;40MG	N88616 001	NOV 09, 1984	APR	CAHN
			ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE						
			CAPSULE; ORAL						
			FIORICET W/ CODEINE						
	AB	+	WATSON PHARMS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CAHN
			ACETAMINOPHEN; CODEINE PHOSPHATE						
			TABLET; ORAL						
			ACETAMINOPHEN AND CODEINE PHOSPAHTE						
	AA		ANDRX PHARMS	300MG;15MG	N40443 001	JAN 22, 2003	JAN	NEWA
	AA			300MG;30MG	N40443 002	JAN 22, 2003	JAN	NEWA
	AA			300MG;60MG	N40443 003	JAN 22, 2003	JAN	NEWA
			ACETAMINOPHEN AND CODEINE PHOSPHATE						
	AA		RANBAXY	300MG;60MG	N87083 001		JAN	CAHN
			ACETAMINOPHEN W/ CODEINE PHOSPHATE #3						
	AA		RANBAXY	300MG;30MG	N85868 001		JAN	CAHN
			CODRIX						
		+	ANDRX PHARMS	500MG;30MG	N40441 001	MAR 27, 2003	MAR	NEWA
		+		500MG;15MG	N40447 001	FEB 26, 2003	FEB	NEWA
		+		500MG;60MG	N40488 001	MAR 28, 2003	MAR	NEWA
			ACETAMINOPHEN; HYDROCODONE BITARTRATE						
			TABLET; ORAL						
			ACETAMINOPHEN AND HYDROCODONE BITARTRATE						
	AA		ABLE	650MG;7.5MG	N40474 001	JAN 02, 2003	JAN	NEWA
			HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	AA		MIKART	325MG;7.5MG	N40432 001	JAN 22, 2003	JAN	NEWA
			ACYCLOVIR						
			CAPSULE; ORAL						
			ACYCLOVIR						
>A>	AB		AAIPHARMA	200MG	N74833 001	APR 22, 1997	APR	CAHN
>D>	AB		AESGEN	200MG	N74833 001	APR 22, 1997	APR	CAHN
			ALBUTEROL SULFATE						
			SOLUTION; INHALATION						
			ALBUTEROL SULFATE						
>A>	AN		NOVEX	EQ 0.5% BASE	N76391 001	APR 01, 2003	APR	NEWA
			ALFENTANIL HYDROCHLORIDE						
			INJECTABLE; INJECTION						
			ALFENTA						
	AP	+	AKORN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986	MAR	CAHN

ALMOTRIPTAN MALATE
TABLET; ORAL
AXERT

>A>		JANSSEN ORTHO	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	APR	CAHN
>A>	+		EQ 12.5MG BASE	N21001 002	MAY 07, 2001	APR	CAHN
>D>		PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	APR	CAHN
>D>	+		EQ 12.5MG BASE	N21001 002	MAY 07, 2001	APR	CAHN

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
INJECTABLE; INJECTION
CERNEVIT-12

@	BAXTER HLTHCARE	11.2 IU/VIAL;125MG/VIAL;60UGM/VIAL;200 IU/VIAL;5.5MG/VIAL;414UGM/VIAL;46MG /VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14 MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL	N20924 001	APR 06, 1999	MAR	DISC

ALPRAZOLAM
TABLET, EXTENDED RELEASE; ORAL
XANAX XR

		PHARMACIA AND UPJOHN	0.5MG	N21434 001	JAN 17, 2003	JAN	NEWA
			1MG	N21434 002	JAN 17, 2003	JAN	NEWA
			2MG	N21434 003	JAN 17, 2003	JAN	NEWA
	+		3MG	N21434 004	JAN 17, 2003	JAN	NEWA

AMANTADINE HYDROCHLORIDE
CAPSULE; ORAL
AMANTADINE HCL

>A>	AB		GENEVA PHARMS	100MG	N71293 001	FEB 18, 1987	APR	CAHN
>D>	AB		GENEVA PHARMS TECH	100MG	N71293 001	FEB 18, 1987	APR	CAHN

AMCINONIDE
CREAM; TOPICAL
AMCINONIDE

>A>								
>A>	AT		TARO PHARM INDS	0.1%	N76229 001	MAY 31, 2002	APR	NEWA
			CYCLOCORT					
>D>		+	FUJISAWA HLTHCARE	0.1%	N18116 002		APR	CFTG
>A>	AT	+		0.1%	N18116 002		APR	CFTG

OINTMENT; TOPICAL
AMCINONIDE

	AB		TARO PHARM INDS	0.1%	N76367 001	MAR 19, 2003	MAR	NEWA

AMIODARONE HYDROCHLORIDE
INJECTABLE; INJECTION
AMIODARONE HCL

>A>	AP		APOTEX	50MG/ML	N76394 001	APR 25, 2003	APR	NEWA
			CORDARONE					
	AP	+	WYETH PHARMS INC	50MG/ML	N20377 001	AUG 03, 1995	MAR	CAHN

TABLET; ORAL

	AB		WYETH PHARMS INC	200MG	N18972 001	DEC 24, 1985	MAR	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	ETRAFON 2-10					
	@ SCHERING	10MG;2MG	N14713 007		MAR	DISC
	ETRAFON 2-25					
	@ SCHERING	25MG;2MG	N14713 004		MAR	DISC
	ETRAFON-FORTE					
	@ SCHERING	25MG;4MG	N14713 006		MAR	DISC

AMMONIUM LACTATE

CREAM; TOPICAL

	AMMONIUM LACTATE					
>A> AB	TARO	EQ 12% BASE	N75883 001	APR 10, 2003	APR	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM					
AB	RANBAXY	200MG/5ML;EQ 28.5MG BASE/5ML	N65132 001	MAR 19, 2003	MAR	NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	N65132 002	MAR 19, 2003	MAR	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

	ADDERALL XR 10					
	SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	JAN	CAHN
	ADDERALL XR 15					
	SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	JAN	CAHN
	ADDERALL XR 20					
	SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	JAN	CAHN
	ADDERALL XR 25					
	SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	JAN	CAHN
	ADDERALL XR 30					
+	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	JAN	CAHN
	ADDERALL XR 5					
	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005	MAY 22, 2002	JAN	CAHN

TABLET; ORAL

	ADDERALL 12.5					
AB	SHIRE LABS	3.125MG;3.125MG;3.125MG;3.125MG	N11522 012	AUG 31, 2000	MAR	CFTG
	ADDERALL 15					
AB	SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N11522 013	AUG 31, 2000	MAR	CFTG
	ADDERALL 7.5					
AB	SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	MAR	CFTG
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB	BARR	1.875MG;1.875MG;1.875MG;1.875MG	N40422 005	MAR 19, 2003	MAR	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	N40422 006	MAR 19, 2003	MAR	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	N40422 007	MAR 19, 2003	MAR	NEWA

AMPRENAVIR

CAPSULE; ORAL

	AGENERASE					
	GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999	MAR	CMFD
+		150MG	N21007 002	APR 15, 1999	MAR	CMFD

	AMPRENAVIR						
	SOLUTION; ORAL						
	AGENERASE						
	+ GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999	MAR	CMFD
	APREPITANT						
	CAPSULE; ORAL						
	EMEND						
	MERCK	80MG	N21549 001	MAR 26, 2003	MAR	NEWA
	+	125MG	N21549 002	MAR 26, 2003	MAR	NEWA
	ASPIRIN; BUTALBITAL; CAFFEINE						
	CAPSULE; ORAL						
	FIORINAL						
AB	+ WATSON PHARMS	325MG;50MG;40MG	N17534 005	APR 16, 1986	MAR	CAHN
	TABLET; ORAL						
AB	+ WATSON PHARMS	325MG;50MG;40MG	N17534 003	APR 16, 1986	MAR	CAHN
	ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE						
	CAPSULE; ORAL						
	FIORINAL W/CODEINE NO 3						
AB	+ WATSON PHARMS	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990	MAR	CAHN
	AZATHIOPRINE						
	TABLET; ORAL						
	AZASAN						
	AAIPHARMA LLC	25MG	N75252 002	FEB 03, 2003	FEB	NEWA
AB		50MG	N75252 001	JUN 07, 1999	FEB	NEWA
		75MG	N75252 003	FEB 03, 2003	FEB	NEWA
		100MG	N75252 004	FEB 03, 2003	FEB	NEWA
	AZELASTINE HYDROCHLORIDE						
	SOLUTION/DROPS; OPHTHALMIC						
	OPTIVAR						
>A>	+ MEDPOINTE	0.05%	N21127 001	MAY 22, 2000	APR	CAHN
>D>	+ MURO	0.05%	N21127 001	MAY 22, 2000	APR	CAHN
	BECLOMETHASONE DIPROPIONATE						
	AEROSOL, METERED; INHALATION						
	BECLOVENT						
	@ GLAXOSMITHKLINE	0.042MG/INH	N18153 001		MAR	DISC
	AEROSOL, METERED; NASAL						
	BECONASE						
	@ GLAXOSMITHKLINE	0.042MG/INH	N18584 001		MAR	DISC
	VANCENASE						
	@ SCHERING	0.042MG/INH	N18521 001		MAR	DISC

BETAMETHASONE
TABLET; ORAL
CELESTONE

	@ SCHERING	0.6MG	N12657 003			FEB	DISC

BISOPROLOL FUMARATE
TABLET; ORAL
ZEBETA

AB	WYETH PHARMS INC	5MG	N19982 002	JUL 31, 1992		MAR	CAHN
AB +		10MG	N19982 001	JUL 31, 1992		MAR	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ZIAC

AB	WYETH PHARMS INC	2.5MG;6.25MG	N20186 003	MAR 26, 1993		MAR	CAHN
AB		5MG;6.25MG	N20186 001	MAR 26, 1993		MAR	CAHN
AB +		10MG;6.25MG	N20186 002	MAR 26, 1993		MAR	CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SYRUP; ORAL
DIMETANE-DX

	@ ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML	N19279 001	AUG 24, 1984		MAR	DISC

MYPHETANE DX

AA +	MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	N88811 001	JUN 07, 1985		MAR	CTEC

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL
BUSPIRONE HCL

AB	EGIS	15MG	N75119 003	JAN 23, 2003		JAN	NEWA

CALCITRIOL
INJECTABLE; INJECTION
CALCITRIOL

AP	AAIPHARMA	0.001MG/ML	N75766 001	FEB 20, 2003		FEB	NEWA
AP		0.002MG/ML	N75766 002	FEB 20, 2003		FEB	NEWA
AP	GENSIA SICOR PHARMS	0.001MG/ML	N75823 001	MAR 31, 2003		MAR	NEWA
AP		0.002MG/ML	N75823 002	MAR 31, 2003		MAR	NEWA

CARBINOXAMINE MALEATE
>A> SOLUTION; ORAL
>A> CARBINOXAMINE MALEATE

>A> +	MIKART	4MG/5ML	N40458 001	APR 25, 2003		APR	NEWA

TABLET; ORAL

+	MIKART	4MG	N40442 001	MAR 19, 2003		MAR	NEWA

CARVEDILOL
TABLET; ORAL
COREG

>D>	GLAXOSMITHKLINE	12.5MG	N20297 002	SEP 14, 1995		APR	CRLD
>A> +		12.5MG	N20297 002	SEP 14, 1995		APR	CRLD
>D> +		25MG	N20297 001	SEP 14, 1995		APR	CRLD
>A>		25MG	N20297 001	SEP 14, 1995		APR	CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB	RANBAXY	EQ 125MG BASE/5ML	N65115 001	MAR 26, 2003	MAR	NEWA
AB		EQ 250MG BASE/5ML	N65115 002	MAR 26, 2003	MAR	NEWA
AB		EQ 500MG BASE/5ML	N65115 003	MAR 26, 2003	MAR	NEWA

DURICEF

AB	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527 002		MAR	CFTG
AB		EQ 250MG BASE/5ML	N50527 003		MAR	CFTG
AB +		EQ 500MG BASE/5ML	N50527 001		MAR	CFTG

>D> CEFIXIME

>D> FOR SUSPENSION; ORAL

>D> SUPRAX

>D>	+ LEDERLE	100MG/5ML	N50622 001	APR 28, 1989	APR	DISC
>A>	@	100MG/5ML	N50622 001	APR 28, 1989	APR	DISC

>D> TABLET; ORAL

>D>	+ LEDERLE	200MG	N50621 001	APR 28, 1989	APR	DISC
>A>	@	200MG	N50621 001	APR 28, 1989	APR	DISC
>D>	+	400MG	N50621 002	APR 28, 1989	APR	DISC
>A>	@	400MG	N50621 002	APR 28, 1989	APR	DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN IN PLASTIC CONTAINER

+	MERCK	EQ 20MG BASE/ML	N63182 001	JAN 25, 1993	MAR	CRLD
+		EQ 40MG BASE/ML	N63182 002	JAN 25, 1993	MAR	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>A>	AB	RANBAXY	EQ 125MG BASE	N65118 001	APR 25, 2003	APR	NEWA
>A>	AB		EQ 250MG BASE	N65118 002	APR 25, 2003	APR	NEWA
>A>	AB		EQ 500MG BASE	N65118 003	APR 25, 2003	APR	NEWA

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM

+	BRISTOL	EQ 1GM BASE/VIAL	N62464 001	MAY 07, 1984	MAR	CRLD
+		EQ 2GM BASE/VIAL	N62464 002	MAY 07, 1984	MAR	CRLD
+		EQ 4GM BASE/VIAL	N62464 003	MAY 07, 1984	MAR	CRLD

KEFLIN

@	LILLY	EQ 1GM BASE/VIAL	N50482 001		MAR	DISC
@		EQ 2GM BASE/VIAL	N50482 002		MAR	DISC
@		EQ 4GM BASE/VIAL	N50482 003		MAR	DISC

CICLOPIROX

SHAMPOO; TOPICAL

LOPROX

+	MEDICIS	1%	N21159 001	FEB 28, 2003	FEB	NEWA

CLADRIBINE
INJECTABLE; INJECTION
LEUSTATIN

>D>		+	ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993	APR	CTEC
>A>	AP	+		1MG/ML	N20229 001	FEB 26, 1993	APR	CTEC

CLINDAMYCIN HYDROCHLORIDE
CAPSULE; ORAL
CLINDAMYCIN HCL

	AB		WATSON LABS	EQ 300MG BASE	N63083 002	MAR 18, 2003	MAR	NEWA

CLONAZEPAM
TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

>D>			@ ROCHE	0.125MG	N20813 001	DEC 23, 1997	APR	CMFD
>A>				0.125MG	N20813 001	DEC 23, 1997	APR	CMFD
>D>			@	0.25MG	N20813 002	DEC 23, 1997	APR	CMFD
>A>				0.25MG	N20813 002	DEC 23, 1997	APR	CMFD
>D>			@	0.5MG	N20813 003	DEC 23, 1997	APR	CMFD
>A>				0.5MG	N20813 003	DEC 23, 1997	APR	CMFD
>D>			@	1MG	N20813 004	DEC 23, 1997	APR	CMFD
>A>		+		1MG	N20813 004	DEC 23, 1997	APR	CMFD
>D>			@	2MG	N20813 005	DEC 23, 1997	APR	CMFD
>A>				2MG	N20813 005	DEC 23, 1997	APR	CMFD

COPPER
INTRAUTERINE DEVICE; INTRAUTERINE
COPPER T MODEL TCU 380A

		+	FEI	309MG/COPPER	N18680 001	NOV 15, 1984	MAR	CAHN

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE

>D>	BP		PHARMACIA AND UPJOHN	25MG	N08126 001		APR	CRLD
>A>	BP	+		25MG	N08126 001		APR	CRLD
>D>			CORTONE					
>D>	BP	+	MERCK	25MG	N07750 003		APR	DISC
>A>			@	25MG	N07750 003		APR	DISC

CYCLOBENZAPRINE HYDROCHLORIDE
TABLET; ORAL
FLEXERIL

>D>	AA		MCNEIL CONS SPECLT	5MG	N17821 001		APR	CTEC
>A>				5MG	N17821 001		APR	CTEC
	AA			5MG	N17821 001		MAR	CMFD

CYCLOSPORINE
CAPSULE; ORAL
GENGRAF

	AB1		ABBOTT	25MG	N65003 001	MAY 12, 2000	FEB	CTNA
	BX			50MG	N65003 002	MAY 12, 2000	FEB	CTNA
	AB1			100MG	N65003 003	MAY 12, 2000	FEB	CTNA

CYCLOSPORINE
EMULSION; OPHTHALMIC
RESTASIS
+ ALLERGAN 0.05% N50790 001 DEC 23, 2002 MAR CMS1

DALFOPRISTIN; QUINUPRISTIN
INJECTABLE; IV (INFUSION)
SYNERCID
+ KING PHARMS 350MG/VIAL;150MG/VIAL N50748 001 SEP 21, 1999 FEB CAHN
@ 420MG/VIAL;180MG/VIAL N50748 002 AUG 24, 2000 FEB CAHN

DEMECLOCYCLINE HYDROCHLORIDE
TABLET; ORAL
DECLOMYCIN
@ WYETH PHARMS INC 75MG N50261 001 MAR CAHN
150MG N50261 002 MAR CAHN
+ 300MG N50261 003 MAR CAHN

>A> DESIRUDIN
>A> INJECTABLE; SUBCUTANEOUS
>A> IPRIVASK
>A> + AVENTIS PHARMS 15MG/VIAL N21271 001 APR 04, 2003 APR NEWA

DESOGESTREL; ETHINYL ESTRADIOL
TABLET; ORAL-21
ORTHO-CEPT
@ ORTHO MCNEIL PHARM 0.15MG;0.03MG N20301 001 DEC 14, 1992 MAR DISC
TABLET; ORAL-28
AB + ORTHO MCNEIL PHARM 0.15MG;0.03MG N20301 002 DEC 14, 1992 MAR CRLD

DEXAMETHASONE
ELIXIR; ORAL
>D> DECADRON
>D> AA + MERCK 0.5MG/5ML N12376 002 APR DISC
>A> @ 0.5MG/5ML N12376 002 APR DISC
HEXADROL
>D> AA ORGANON 0.5MG/5ML N12674 001 APR CRLD
>A> AA + 0.5MG/5ML N12674 001 APR CRLD

DEXAMETHASONE SODIUM PHOSPHATE
INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
>A> AP AM PHARM EQ 10MG PHOSPHATE/ML N40491 001 APR 11, 2003 APR NEWA

DIGOXIN
TABLET; ORAL
DIGOXIN
AB CARACO 0.125MG N76363 001 JAN 31, 2003 JAN NEWA
AB 0.25MG N76363 002 JAN 31, 2003 JAN NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

>D>		XCEL PHARMS	1MG/ML	N05929 001		APR	CFTG
>A>	AP +		1MG/ML	N05929 001		APR	CFTG
>A>		DIHYDROEROGTAMINE MESYLATE					
>A>	AP	PADDOCK	1MG/ML	N40475 001	APR 28, 2003	APR	NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

>A>		TAZTIA XT					
>A>	AB4	ANDRX PHARMS	120MG	N75401 001	APR 10, 2003	APR	NEWA
>A>	AB4		180MG	N75401 002	APR 10, 2003	APR	NEWA
>A>	AB4		240MG	N75401 003	APR 10, 2003	APR	NEWA
>A>	AB4		300MG	N75401 004	APR 10, 2003	APR	NEWA
>A>	AB4		360MG	N75401 005	APR 10, 2003	APR	NEWA
		TIAZAC					
>D>	BC +	BIOVAIL	120MG	N20401 001	SEP 11, 1995	APR	CFTG
>A>	AB4 +		120MG	N20401 001	SEP 11, 1995	APR	CFTG
>D>	BC +		180MG	N20401 002	SEP 11, 1995	APR	CFTG
>A>	AB4 +		180MG	N20401 002	SEP 11, 1995	APR	CFTG
>D>	BC +		240MG	N20401 003	SEP 11, 1995	APR	CFTG
>A>	AB4 +		240MG	N20401 003	SEP 11, 1995	APR	CFTG
>D>	BC +		300MG	N20401 004	SEP 11, 1995	APR	CFTG
>A>	AB4 +		300MG	N20401 004	SEP 11, 1995	APR	CFTG
>D>	+		360MG	N20401 005	SEP 11, 1995	APR	CFTG
>A>	AB4 +		360MG	N20401 005	SEP 11, 1995	APR	CFTG

TABLET, EXTENDED RELEASE; ORAL

		CARDIZEM LA					
	+	BIOVAIL	120MG	N21392 001	FEB 06, 2003	FEB	NEWA
	+		180MG	N21392 002	FEB 06, 2003	FEB	NEWA
	+		240MG	N21392 003	FEB 06, 2003	FEB	NEWA
	+		300MG	N21392 004	FEB 06, 2003	FEB	NEWA
	+		360MG	N21392 005	FEB 06, 2003	FEB	NEWA
	+		420MG	N21392 006	FEB 06, 2003	FEB	NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

		DOPRAM					
AP	+	BAXTER HLTHCARE CORP	20MG/ML	N14879 001		JAN	CAHN
		DOXAPRAM HCL					
AP		BEDFORD	20MG/ML	N76266 001	JAN 10, 2003	JAN	NEWA

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL

		DORYX					
		FAULDING	EQ 75MG BASE	N50582 002	AUG 13, 2001	FEB	NEWA

INJECTABLE; INJECTION

		DOXY 100					
	+	AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001	DEC 09, 1983	MAR	CRLD
		DOXY 200					
	+	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002	DEC 09, 1983	MAR	CRLD

DOXYCYCLINE HYCLATE
INJECTABLE; INJECTION
VIBRAMYCIN

		@ PFIZER	EQ 100MG BASE/VIAL	N50442 002		MAR	DISC
		@	EQ 200MG BASE/VIAL	N50442 001		MAR	DISC

ELETRIPTAN HYDROBROMIDE
TABLET; ORAL
RELPAX

		PFIZER IRELAND	EQ 20MG BASE	N21016 001	DEC 26, 2002	MAR	CAHN
	+		EQ 40MG BASE	N21016 002	DEC 26, 2002	MAR	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		IVAX PHARMS	5MG;12.5MG	N75736 001	MAR 25, 2003	MAR	NEWA
AB			10MG;25MG	N75736 002	MAR 25, 2003	MAR	NEWA

ENFUVIRTIDE
INJECTABLE; SUBCUTANEOUS
FUZEON

	+	ROCHE	90MG/VIAL	N21481 001	MAR 13, 2003	MAR	NEWA

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX

	+	AVENTIS	300MG/3ML	N20164 009	JAN 23, 2003	JAN	NEWA

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

		@ DENTSPLY PHARM	0.005MG/ML;1.5%	N21384 001		MAR	DISC

ERGOTAMINE TARTRATE
TABLET; SUBLINGUAL
ERGOMAR

	+	HARVEST PHARMS	2MG	N87693 001	FEB 24, 1983	MAR	CAHN

ERYTHROMYCIN
SOLUTION; TOPICAL
STATICIN

>D>	AT +	WESTWOOD SQUIBB	1.5%	N50526 001		APR	CTEC
>A>	+		1.5%	N50526 001		APR	CTEC

ESMOLOL HYDROCHLORIDE
INJECTABLE; INJECTION
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE CORP	2GM/100ML	N19386 005	JAN 27, 2003	MAR	NEWA

BREVIBLOC IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE CORP	1GM/100ML	N19386 004	FEB 16, 2001	MAR	NEWA

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

	GALEN LTD	0.05MG/24HR	N21367 001	MAR 20, 2003	MAR	NEWA
+		0.1MG/24HR	N21367 002	MAR 20, 2003	MAR	NEWA

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+	WYETH PHARMS INC	0.625MG/GM	N20216 001		MAR	CAHN

INJECTABLE; INJECTION

+	WYETH PHARMS INC	25MG/VIAL	N10402 001		MAR	CAHN

TABLET; ORAL

	WYETH PHARMS INC	0.3MG	N04782 003		MAR	CAHN
+		0.625MG	N04782 004		MAR	CAHN
		0.9MG	N04782 005	JAN 26, 1984	MAR	CAHN
+		1.25MG	N04782 001		MAR	CAHN
		2.5MG	N04782 002		MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

@	WYETH PHARMS INC	0.625MG,0.625MG;5MG	N20303 002	DEC 30, 1994	MAR	CAHN

PREMPHASE 14/14

+	WYETH PHARMS INC	0.625MG,0.625MG;5MG	N20527 002	NOV 17, 1995	MAR	CAHN

PREMPRO

+	WYETH PHARMS INC	0.45MG;1.5MG	N20527 004	MAR 12, 2003	MAR	NEWA
+		0.625MG,0.625MG;2.5MG,2.5MG	N20527 001	NOV 17, 1995	MAR	CAHN
+		0.625MG,0.625MG;5MG,5MG	N20527 003	JAN 09, 1998	MAR	CAHN

PREMPRO (PREMARIN;CYCRIN)

@	WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N20303 001	DEC 30, 1994	MAR	CAHN

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

	MONARCH PHARMS	0.3MG	N84951 001		JAN	CRLD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB1	+	WYETH PHARMS INC	0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAR	CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A>	AB1		BARR	0.02MG;0.1MG	N75862 001	APR 29, 2003	APR	NEWA

NORDETTE-21

AB	+	WYETH PHARMS INC	0.03MG;0.15MG	N18668 001	MAY 10, 1982	MAR	CAHN

TRIPHASIL-21

AB	+	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.125MG ,0.075MG	N19192 001	NOV 01, 1984	MAR	CAHN

TABLET; ORAL-28

ALESSE

AB1		WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	MAR 27, 1997	MAR	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A>	AB1	BARR	0.02MG;0.1MG	N75862	002	APR 29, 2003	APR	NEWA
		NORDETTE-28						
	AB	WYETH PHARMS INC	0.03MG;0.15MG	N18782	001	JUL 21, 1982	MAR	CAHN
		TRIPHASIL-28						
	AB	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.125MG ,0.075MG	N19190	001	NOV 01, 1984	MAR	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

		TRI-NORINYL 21-DAY						
		@ WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .5MG	N18977	001	APR 13, 1984	MAR	CPOT
		@	0.035MG,0.035MG;0.5MG,1MG	N18977	001	APR 13, 1984	FEB	DISC

TABLET; ORAL-28

		ORTHO-NOVUM 7/7/7-28						
	AB +	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985	002	APR 04, 1984	FEB	CRLD
		OVCON-35						
	+	WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		JAN	CRLD
		OVCON-50						
	+	WARNER CHILCOTT	0.05MG;1MG	N17576	001		JAN	CRLD
		TRI-NORINYL 28-DAY						
	+	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .5MG	N18977	002	APR 13, 1984	MAR	CPOT
	+		0.035MG,0.035MG;0.5MG,1MG	N18977	002	APR 13, 1984	JAN	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

		ESTROSTEP 21						
>A>		@ GALEN CHEM	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	001	OCT 09, 1996	APR	CAHN
>D>		@ PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	001	OCT 09, 1996	APR	CAHN
		LOESTRIN 21 1.5/30						
>A>	+	GALEN CHEM	0.03MG;1.5MG	N17875	001		APR	CAHN
>D>	+	PARKE DAVIS	0.03MG;1.5MG	N17875	001		APR	CAHN
		LOESTRIN 21 1/20						
>A>	+	GALEN CHEM	0.02MG;1MG	N17876	001		APR	CAHN
>D>	+	PARKE DAVIS	0.02MG;1MG	N17876	001		APR	CAHN

TABLET; ORAL-28

		ESTROSTEP FE						
>A>	+	GALEN CHEM	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	002	OCT 09, 1996	APR	CAHN
>D>	+	PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	002	OCT 09, 1996	APR	CAHN
		LOESTRIN FE 1.5/30						
>A>	AB +	GALEN CHEM	0.03MG;1.5MG	N17355	001		APR	CAHN
>D>	AB +	PARKE DAVIS	0.03MG;1.5MG	N17355	001		APR	CAHN
		LOESTRIN FE 1/20						
>A>	AB +	GALEN CHEM	0.02MG;1MG	N17354	001		APR	CAHN
>D>	AB +	PARKE DAVIS	0.02MG;1MG	N17354	001		APR	CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

AB	+	WYETH PHARMS INC	0.03MG;0.3MG	N17612	001		MAR	CAHN

OGESTREL 0.5/50-21

AB		WATSON LABS	0.05MG;0.5MG	N75406	001	DEC 15, 1999	FEB	CAHN

OVRAL

AB	+	WYETH PHARMS INC	0.05MG;0.5MG	N16672	001		MAR	CAHN

TABLET; ORAL-28

LO/OVRAL-28

AB		WYETH PHARMS INC	0.03MG;0.3MG	N17802	001		MAR	CAHN

OGESTREL 0.5/50-28

AB		WATSON LABS	0.05MG;0.5MG	N75406	002	DEC 15, 1999	FEB	CAHN

OVRAL-28

AB		WYETH PHARMS INC	0.05MG;0.5MG	N16806	001		MAR	CAHN

ETHIONAMIDE

TABLET; ORAL

TRECATOR-SC

	+	WYETH PHARMS INC	250MG	N13026	002		MAR	CAHN

ETHOTOIN

TABLET; ORAL

PEGANONE

	+	OVATION PHARMS	250MG	N10841	001		MAR	CAHN
		@	500MG	N10841	003		MAR	CAHN

ETIDRONATE DISODIUM

TABLET; ORAL

ETIDRONATE DISODIUM

AB		GENPHARM	200MG	N75800	001	JAN 24, 2003	JAN	NEWA
AB			400MG	N75800	002	JAN 24, 2003	JAN	NEWA

ETODOLAC

CAPSULE; ORAL

LODINE

AB		WYETH PHARMS INC	200MG	N18922	002	JAN 31, 1991	MAR	CAHN
AB	+		300MG	N18922	003	JAN 31, 1991	MAR	CAHN

TABLET; ORAL

AB		WYETH PHARMS INC	400MG	N18922	004	JUL 29, 1993	MAR	CAHN
AB	+		500MG	N18922	005	JUN 28, 1996	MAR	CAHN

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB		TARO	400MG	N76174	001	MAR 13, 2003	MAR	NEWA
AB			500MG	N76174	002	MAR 13, 2003	MAR	NEWA
AB			600MG	N76174	003	MAR 13, 2003	MAR	NEWA

LODINE XL

AB	+	WYETH PHARMS INC	400MG	N20584	001	OCT 25, 1996	MAR	CAHN
AB	+		500MG	N20584	003	JAN 20, 1998	MAR	CAHN
AB	+		600MG	N20584	002	OCT 25, 1996	MAR	CAHN

FELBAMATE
SUSPENSION; ORAL
FELBATOL
\+ MEDPOINTE 600MG/5ML N20189 003 JUL 29, 1993 MAR CAHN
TABLET; ORAL
MEDPOINTE 400MG N20189 001 JUL 29, 1993 MAR CAHN
\+ 600MG N20189 002 JUL 29, 1993 MAR CAHN

FENOFIBRATE
CAPSULE; ORAL
FENOFIBRATE (MICRONIZED)
TEVA 67MG N75753 001 SEP 03, 2002 MAR CTEC
134MG N75753 002 APR 09, 2002 MAR CTEC
\+ 200MG N75753 003 APR 09, 2002 MAR CRLD
TRICOR (MICRONIZED)
@ ABBOTT 67MG N19304 002 FEB 09, 1998 MAR DISC
@ 134MG N19304 003 JUN 30, 1999 MAR DISC
@ 200MG N19304 004 JUN 30, 1999 MAR DISC

FLAVOXATE HYDROCHLORIDE
TABLET; ORAL
URISPAS
\+ ORTHO-MCNEIL PHARMAC 100MG N16769 001 MAR CAHN

FLECAINIDE ACETATE
TABLET; ORAL
FLECAINIDE ACETATE
AB RANBAXY 50MG N76421 001 MAR 28, 2003 MAR NEWA
AB 100MG N76421 002 MAR 28, 2003 MAR NEWA
AB 150MG N76421 003 MAR 28, 2003 MAR NEWA
AB ROXANE 50MG N76278 001 JAN 14, 2003 JAN NEWA
AB 100MG N76278 002 JAN 14, 2003 JAN NEWA
AB 150MG N76278 003 JAN 14, 2003 JAN NEWA

FLUDROCORTISONE ACETATE
TABLET; ORAL
FLUDROCORTISONE ACETATE
AB BARR 0.1MG N40425 001 JAN 21, 2003 JAN NEWA

FLUORESCEIN SODIUM
INJECTABLE; INJECTION
FUNDUSCEIN-25
@ NOVARTIS 25% N17869 001 JAN DISC

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE
>A> AB GENEVA PHARMS 25MG N75887 001 JAN 05, 2001 APR CAHN
>A> AB 50MG N75887 002 JAN 05, 2001 APR CAHN
>A> AB 100MG N75887 003 JAN 05, 2001 APR CAHN
>D> AB INVAMED 25MG N75887 001 JAN 05, 2001 APR CAHN
>D> AB 50MG N75887 002 JAN 05, 2001 APR CAHN

>D>	AB	100MG	N75887 003	JAN 05, 2001	APR	CAHN

FOLIC ACID
INJECTABLE; INJECTION
FOLVITE

AP	+ WYETH PHARMS INC	5MG/ML	N05897 008		MAR	CAHN

TABLET; ORAL

	@ WYETH PHARMS INC	1MG	N05897 004		MAR	CAHN

GALANTAMINE HYDROBROMIDE
TABLET; ORAL
REMINYL

>D>	JANSSEN PHARMA	EQ 4MG BASE	N21169 001	FEB 28, 2001	APR	CRLD
>A>	+	EQ 4MG BASE	N21169 001	FEB 28, 2001	APR	CRLD
>D>	+	EQ 12MG BASE	N21169 003	FEB 28, 2001	APR	CRLD
>A>		EQ 12MG BASE	N21169 003	FEB 28, 2001	APR	CRLD

GATIFLOXACIN
INJECTABLE; INJECTION
TEQUIN

>D>	BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)	N21062 001	DEC 17, 1999	APR	CRLD
>D>		EQ 2MG /ML(400MG/200ML)	N21062 002	DEC 17, 1999	APR	CRLD
>A>	+	EQ 2MG /ML(200MG/100ML)	N21062 001	DEC 17, 1999	APR	CRLD
>A>	+	EQ 2MG /ML(400MG/200ML)	N21062 002	DEC 17, 1999	APR	CRLD
>D>		EQ 10MG /ML(200MG)	N21062 003	DEC 17, 1999	APR	CRLD
>A>	+	EQ 10MG /ML(200MG)	N21062 003	DEC 17, 1999	APR	CRLD

SOLUTION/DROPS; OPHTHALMIC
ZYMAR

	+ ALLERGAN	0.3%	N21493 001	MAR 28, 2003	MAR	NEWA

>A>	GEMIFLOXACIN MESYLATE					
>A>	TABLET; ORAL					
>A>	FACTIVE					
>A>	+ LG LIFE	EQ 320MG BASE	N21158 001	APR 04, 2003	APR	NEWA

GEMTUZUMAB OZOGAMICIN
INJECTABLE; INJECTION
MYLOTARG

	+ WYETH PHARMS INC	5MG/VIAL	N21174 001	MAY 17, 2000	MAR	CAHN

GENTAMICIN SULFATE
CREAM; TOPICAL
GARAMYCIN

	@ SCHERING	EQ 0.1% BASE	N60462 001		FEB	DISC

GENTAMICIN SULFATE

AT	+ FOUGERA	EQ 0.1% BASE	N62531 001	JUL 05, 1984	FEB	CRLD

OINTMENT; OPHTHALMIC

>D>	GARAMYCIN					
>D>	AT + SCHERING	EQ 0.3% BASE	N50425 001		APR	DISC
>A>	@	EQ 0.3% BASE	N50425 001		APR	DISC

GENTAMICIN SULFATE

>D>	AT AKORN	EQ 0.3% BASE	N64093 001	AUG 31, 1995	APR	CRLD
>A>	+	EQ 0.3% BASE	N64093 001	AUG 31, 1995	APR	CRLD

GLIMEPIRIDE
TABLET; ORAL
AMARYL

+	AVENTIS PHARMS	1MG	N20496 001	NOV 30, 1995	JAN	CRLD
		4MG	N20496 003	NOV 30, 1995	JAN	CRLD

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE
TABLET; ORAL
INDERIDE-40/25

AB	WYETH PHARMS INC	25MG;40MG	N18031 001		MAR	CAHN

INDERIDE-80/25

AB	+ WYETH PHARMS INC	25MG;80MG	N18031 002		MAR	CAHN

HYDROCODONE BITARTRATE; IBUPROFEN
TABLET; ORAL

>A>	HYDROCODONE BITARTRATE AND IBUPROFEN					
>A>	AB	TEVA	7.5MG;200MG	N76023 001	APR 11, 2003	APR	NEWA

VICOPROFEN

>D>	+ ABBOTT	7.5MG;200MG	N20716 001	SEP 23, 1997	APR	CFTG
>A>	AB +	7.5MG;200MG	N20716 001	SEP 23, 1997	APR	CFTG

>D> HYDROCORTISONE SODIUM PHOSPHATE
>D> INJECTABLE; INJECTION
>D> HYDROCORTONE

>D>	+ MERCK	EQ 50MG BASE/ML	N12052 001		APR	DISC
>A>	@	EQ 50MG BASE/ML	N12052 001		APR	DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001	AUG 25, 1983	FEB	CMFD

SUSPENSION/DROPS; OPHTHALMIC

AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	FEB	CMFD

SUSPENSION/DROPS; OTIC

AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001	NOV 06, 1985	FEB	CMFD

HYDROMORPHONE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDROMORPHONE HCL

>A>	AP	FAULDING	10MG/ML	N76444 001	APR 25, 2003	APR	NEWA

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
ATARAX

	@ PFIZER	10MG	N10392 001		FEB	DISC
	@	25MG	N10392 004		FEB	DISC
	@	50MG	N10392 006		FEB	DISC
	@	100MG	N10392 005		FEB	DISC

HYDROXYZINE HCL

AB	+ SIDMAK LABS NJ	10MG	N88617 001	JAN 10, 1986	FEB	CRLD
AB	+	25MG	N88618 001	JAN 10, 1986	FEB	CRLD
AB	+	50MG	N88619 001	JAN 10, 1986	FEB	CRLD

		@	100MG	N81054 001	SEP 25, 1995	FEB	DISC

IMATINIB MESYLATE

>A>		TABLET; ORAL						
>A>		GLEEVEC						
>A>		NOVARTIS	100MG	N21588 001	APR 18, 2003	APR	NEWA	
>A>	+		400MG	N21588 002	APR 18, 2003	APR	NEWA	

IPRATROPIUM BROMIDE

		SPRAY, METERED; NASAL						
		ATROVENT						
	AB +	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N20393 001	OCT 20, 1995	MAR	CFTG	
	AB +		0.042MG/SPRAY	N20394 001	OCT 20, 1995	MAR	CFTG	
		IPRATROPIUM BROMIDE						
	AB	BAUSCH AND LOMB	0.021MG/SPRAY	N76025 001	MAR 31, 2003	MAR	NEWA	
	AB		0.042MG/SPRAY	N76103 001	MAR 31, 2003	MAR	NEWA	
	AB	DEY	0.021MG/SPRAY	N75552 001	MAR 31, 2003	MAR	NEWA	
	AB		0.042MG/SPRAY	N75553 001	MAR 31, 2003	MAR	NEWA	
>A>	AB	NOVEX	0.021MG/SPRAY	N76156 001	APR 18, 2003	APR	NEWA	
>A>	AB		0.042MG/SPRAY	N76155 001	APR 18, 2003	APR	NEWA	

ISOSORBIDE DINITRATE

		TABLET; ORAL						
		ISORDIL						
	AB	WYETH PHARMS INC	5MG	N12093 007	JUL 29, 1988	MAR	CAHN	
	AB		10MG	N12093 002	JUL 29, 1988	MAR	CAHN	
	AB		20MG	N12093 006	JUL 29, 1988	MAR	CAHN	
	AB +		30MG	N12093 005	JUL 29, 1988	MAR	CAHN	
	AB		40MG	N12093 001	JUL 29, 1988	MAR	CAHN	
		TABLET; SUBLINGUAL						
	AB	WYETH PHARMS INC	2.5MG	N12940 004	JUL 29, 1988	MAR	CAHN	
	AB		5MG	N12940 003	JUL 29, 1988	MAR	CAHN	
	+		10MG	N12940 005	JUL 29, 1988	MAR	CAHN	

ISOTRETINOIN

		CAPSULE; ORAL						
		CLARAVIS						
>A>	AB	BARR	10MG	N76356 001	APR 11, 2003	APR	NEWA	
>A>	AB		20MG	N76135 002	APR 11, 2003	APR	NEWA	
>A>	AB		40MG	N76135 001	APR 11, 2003	APR	NEWA	

KETOPROFEN

		CAPSULE, EXTENDED RELEASE; ORAL						
		ORUVAIL						
	AB	WYETH PHARMS INC	100MG	N19816 003	FEB 08, 1995	MAR	CAHN	
	AB		150MG	N19816 002	FEB 08, 1995	MAR	CAHN	
	AB +		200MG	N19816 001	SEP 24, 1993	MAR	CAHN	

LACTULOSE

		SOLUTION; ORAL						
		LACTULOSE						
	AA	VISTAPHARM	10GM/15ML	N74138 001	SEP 30, 1992	MAR	CAHN	

LEFLUNOMIDE
TABLET; ORAL
ARAVA

+	AVENTIS PHARMS	20MG	N20905	002	SEP 10, 1998	MAR	CRLD
@		100MG	N20905	003	SEP 10, 1998	MAR	DISC

LEUPROLIDE ACETATE
INJECTABLE; SUBCUTANEOUS
ELIGARD

+	ATRIX	30MG/VIAL	N21488	001	FEB 13, 2003	FEB	NEWA

LEVOBETAXOLOL HYDROCHLORIDE
SUSPENSION/DROPS; OPHTHALMIC
BETAXON

+	MEDPOINTE	EQ 0.5% BASE	N21114	001	FEB 23, 2000	MAR	CAHN

LEVONORGESTREL
IMPLANT; IMPLANTATION
LEVONORGESTREL

BX	+	WYETH PHARMS INC	75MG/IMPLANT	N20627	001	AUG 15, 1996	MAR	CAHN

NORPLANT SYSTEM IN PLASTIC CONTAINER

+	WYETH PHARMS INC	36MG/IMPLANT	N20088	001	DEC 10, 1990	MAR	CAHN

LEVORPHANOL TARTRATE
TABLET; ORAL
LEVO-DROMORAN

@	ICN	2MG	N08720	001	DEC 19, 1991	FEB	DISC

LEVORPHANOL TARTRATE

+	ROXANE	2MG	N74278	001	MAR 31, 2000	FEB	CRLD

LEVOTHYROXINE SODIUM
TABLET; ORAL
LEVO-T

>A>	BX		ALARA PHARM	0.025MG	N21342	001	MAR 01, 2002	APR	CAHN
>A>	BX			0.05MG	N21342	002	MAR 01, 2002	APR	CAHN
>A>	BX			0.075MG	N21342	003	MAR 01, 2002	APR	CAHN
>A>	BX			0.088MG	N21342	004	MAR 01, 2002	APR	CAHN
>A>	BX			0.1MG	N21342	005	MAR 01, 2002	APR	CAHN
>A>	BX			0.112MG	N21342	006	MAR 01, 2002	APR	CAHN
>A>	BX			0.125MG	N21342	007	MAR 01, 2002	APR	CAHN
>A>	BX			0.15MG	N21342	008	MAR 01, 2002	APR	CAHN
>A>	BX			0.175MG	N21342	009	MAR 01, 2002	APR	CAHN
>A>	BX			0.2MG	N21342	010	MAR 01, 2002	APR	CAHN
>A>	BX	+		0.3MG	N21342	011	MAR 01, 2002	APR	CAHN
>D>	BX		MOVA	0.025MG	N21342	001	MAR 01, 2002	APR	CAHN
>D>	BX			0.05MG	N21342	002	MAR 01, 2002	APR	CAHN
>D>	BX			0.075MG	N21342	003	MAR 01, 2002	APR	CAHN
>D>	BX			0.088MG	N21342	004	MAR 01, 2002	APR	CAHN
>D>	BX			0.1MG	N21342	005	MAR 01, 2002	APR	CAHN
>D>	BX			0.112MG	N21342	006	MAR 01, 2002	APR	CAHN
>D>	BX			0.125MG	N21342	007	MAR 01, 2002	APR	CAHN
>D>	BX			0.15MG	N21342	008	MAR 01, 2002	APR	CAHN

>D>	BX		0.175MG	N21342 009	MAR 01, 2002	APR	CAHN
>D>	BX		0.2MG	N21342 010	MAR 01, 2002	APR	CAHN
>D>	BX	+	0.3MG	N21342 011	MAR 01, 2002	APR	CAHN

LIDOCAINE HYDROCHLORIDE
JELLY; TOPICAL
LIDOCAINE HCL

AT		AKORN	2%	N40433 001	FEB 12, 2003	FEB	NEWA

LISINOPRIL
TABLET; ORAL
LISINOPRIL

AB		RANBAXY	30MG	N75944 006	FEB 11, 2003	FEB	NEWA

ZESTRIL

>D>	AB	+ ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	APR	CRLD
>A>	AB		30MG	N19777 006	JAN 20, 1999	APR	CRLD

LITHIUM CARBONATE
CAPSULE; ORAL
LITHIUM CARBONATE

AB		ROXANE	150MG	N17812 002	JAN 28, 1987	FEB	CTEC
AB		WEST WARD	150MG	N76243 002	FEB 24, 2003	FEB	NEWA

TABLET, EXTENDED RELEASE; ORAL

>A>	AB	ABLE	300MG	N76382 001	APR 21, 2003	APR	NEWA

LORAZEPAM
INJECTABLE; INJECTION
ATIVAN

AP	+	BAXTER HLTHCARE CORP	2MG/ML	N18140 001		FEB	CAHN
AP	+		4MG/ML	N18140 002		FEB	CAHN

MECAMYLAMINE HYDROCHLORIDE
TABLET; ORAL
INVERSINE

>D>	+	LAYTON	2.5MG	N10251 001		APR	CAHN
>A>	+	TARGACEPT	2.5MG	N10251 001		APR	CAHN

MEFLOQUINE HYDROCHLORIDE
TABLET; ORAL
MEFLOQUINE HCL

>A>	AB	GENEVA PHARMS	250MG	N76175 001	FEB 20, 2002	APR	CAHN
>D>	AB	GENEVA PHARMS TECH	250MG	N76175 001	FEB 20, 2002	APR	CAHN

MEPHENTERMINE SULFATE
INJECTABLE; INJECTION
WYAMINE SULFATE

		@ BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N08248 002		FEB	CAHN
		@	EQ 30MG BASE/ML	N08248 001		FEB	CAHN

MEPROBAMATE
TABLET; ORAL
MILTOWN

>A>	AA	+ MEDPOINTE	600MG	N83919 001		APR	CAHN

>D>	AA	+	WALLACE PHARMS	600MG	N83919 001		APR	CAHN

METFORMIN HYDROCHLORIDE
TABLET; ORAL
METFORMIN HCL

	AB		PUREPAC PHARM	1GM	N76033 003	JAN 24, 2002	FEB	CMS1

TABLET, EXTENDED RELEASE; ORAL
GLUCOPHAGE XR

>A>		+	BRISTOL MYERS SQUIBB	750MG	N21202 004	APR 11, 2003	APR	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE
TABLET; ORAL
AVANDAMET

>D>			GLAXOSMITHKLINE	500MG;EQ 1MG BASE	N21410 001	OCT 10, 2002	APR	CAHN
>D>				500MG;EQ 2MG BASE	N21410 002	OCT 10, 2002	APR	CAHN
>D>		+		500MG;EQ 4MG BASE	N21410 003	OCT 10, 2002	APR	CAHN
>A>			SB PHARMCO	500MG;EQ 1MG BASE	N21410 001	OCT 10, 2002	APR	CAHN
>A>		+		500MG;EQ 4MG BASE	N21410 003	OCT 10, 2002	APR	CAHN
>A>				500MG;EQ 2MG BASE	N21410 002	OCT 10, 2002	APR	CAHN

METHADONE HYDROCHLORIDE
INJECTABLE; INJECTION
DOLOPHINE HCL

>A>		+	AAIPHARMA	10MG/ML	N21624 001		APR	CAHN
>D>		+	ROXANE	10MG/ML	N21624 001		APR	CAHN
		+		10MG/ML	N21624 001		FEB	CMS1

METHOCARBAMOL
TABLET; ORAL
METHOCARBAMOL

	AA		ABLE	500MG	N40413 001	MAR 17, 2003	MAR	NEWA
	AA			750MG	N40413 002	MAR 17, 2003	MAR	NEWA
	AA		LANNETT	500MG	N84756 002	MAR 31, 2003	MAR	NEWA
	AA		VINTAGE PHARMS	500MG	N40489 001	JAN 29, 2003	JAN	NEWA
	AA			750MG	N40489 002	JAN 29, 2003	JAN	NEWA

METHOTREXATE SODIUM
INJECTABLE; INJECTION
METHOTREXATE LPF

	AP	+	WYETH PHARMS INC	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982	MAR	CAHN

METHOTREXATE SODIUM

		@	WYETH PHARMS INC	EQ 2.5MG BASE/ML	N11719 004		MAR	CAHN
		+		EQ 20MG BASE/VIAL	N11719 001		MAR	CAHN
	AP	+		EQ 25MG BASE/ML	N11719 005		MAR	CAHN
		@		EQ 50MG BASE/VIAL	N11719 003		MAR	CAHN
		@		EQ 100MG BASE/VIAL	N11719 006		MAR	CAHN

METHOTREXATE SODIUM PRESERVATIVE FREE

	AP	+	WYETH PHARMS INC	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988	MAR	CAHN

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
PAMINE FORTE

		+	BRADLEY PHARMS	5MG	N08848 002	MAR 25, 2003	MAR	NEWA

		METHYLPHENIDATE HYDROCHLORIDE						
>A>		TABLET, CHEWABLE; ORAL						
>A>		METHYLIN						
>A>		MALLINCKRODT	2.5MG	N21475	001	APR 15, 2003	APR	NEWA
>A>			5MG	N21475	002	APR 15, 2003	APR	NEWA
>A>	+		10MG	N21475	003	APR 15, 2003	APR	NEWA
		METOCLOPRAMIDE HYDROCHLORIDE						
		SOLUTION; ORAL						
		METOCLOPRAMIDE						
>D>	AA	UDL	EQ 5MG BASE/5ML	N75051	001	JAN 26, 2001	APR	CAHN
>A>	AA	VISTAPHARM	EQ 5MG BASE/5ML	N75051	001	JAN 26, 2001	APR	CAHN
		MINOCYCLINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		MINOCIN						
	AB	WYETH PHARMS INC	EQ 50MG BASE	N50649	001	MAY 31, 1990	MAR	CAHN
	AB		EQ 75MG BASE	N50649	003	FEB 12, 2001	MAR	CAHN
	AB +		EQ 100MG BASE	N50649	002	MAY 31, 1990	MAR	CAHN
		INJECTABLE; INJECTION						
	+	WYETH PHARMS INC	EQ 100MG BASE/VIAL	N50444	001		MAR	CAHN
>A>		TABLET; ORAL						
>A>		MINOCYCLINE HCL						
>A>		PAR PHARM	EQ 50MG BASE	N65131	001	APR 16, 2003	APR	NEWA
>A>			EQ 75MG BASE	N65131	002	APR 16, 2003	APR	NEWA
>A>	+		EQ 100MG BASE	N65131	003	APR 16, 2003	APR	NEWA
		MIRTAZAPINE						
		TABLET; ORAL						
		MIRTAZAPINE						
	AB	TEVA	15MG	N76119	001	JAN 24, 2003	JAN	NEWA
	AB		30MG	N76119	002	JAN 24, 2003	JAN	NEWA
		REMERON						
	AB +	ORGANON	15MG	N20415	001	JUN 14, 1996	JAN	CFTG
	AB		30MG	N20415	002	JUN 14, 1996	JAN	CFTG
		MOXIFLOXACIN HYDROCHLORIDE						
>A>		SOLUTION/DROPS; OPHTHALMIC						
>A>		VIGAMOX						
>A>	+	ALCON	0.5%	N21598	001	APR 15, 2003	APR	NEWA
		MUPIROCIN						
		OINTMENT; TOPICAL						
		MUPIROCIN						
>D>	BX	CLAY PARK LABS	2%	N50788	001	DEC 04, 2002	APR	CAHN
	BX		2%	N50788	001	DEC 04, 2002	JAN	CTEC
>A>	BX	JOHNSON AND JOHNSON	2%	N50788	001	DEC 04, 2002	APR	CAHN
		MYCOPHENOLATE MOFETIL						
		CAPSULE; ORAL						
		CELLCEPT						
	+	ROCHE PALO	250MG	N50722	001	MAY 03, 1995	FEB	CAHN

		MYCOPHENOLATE MOFETIL						
		SUSPENSION; ORAL						
		CELLCEPT						
	+	ROCHE PALO	200MG/ML	N50759 001	OCT 01, 1998	FEB	CAHN
		TABLET; ORAL						
	+	ROCHE PALO	500MG	N50723 001	JUN 19, 1997	FEB	CAHN
		MYCOPHENOLATE MOFETIL HYDROCHLORIDE						
		INJECTABLE; INJECTION						
	+	ROCHE PALO	500MG/VIAL	N50758 001	AUG 12, 1998	FEB	CAHN
		NABUMETONE						
		TABLET; ORAL						
		NABUMETONE						
AB		IVAX PHARMS	500MG	N76009 001	JAN 24, 2003	JAN	NEWA
AB			750MG	N76009 002	JAN 24, 2003	JAN	NEWA
		NAPROXEN SODIUM						
		TABLET, EXTENDED RELEASE; ORAL						
		NAPRELAN						
>D>	+	ELAN PHARM	EQ 375MG BASE	N20353 001	JAN 05, 1996	APR	CFTG
>A> AB	+		EQ 375MG BASE	N20353 001	JAN 05, 1996	APR	CFTG
AB	+		EQ 500MG BASE	N20353 002	JAN 05, 1996	MAR	CFTG
>A>		NAPROXEN SODIUM						
>A> AB		ANDRX PHARMS	EQ 375MG BASE	N75416 002	APR 23, 2003	APR	NEWA
AB			EQ 500MG BASE	N75416 001	AUG 27, 2002	MAR	NEWA
		NELFINAVIR MESYLATE						
		TABLET; ORAL						
		VIRACEPT						
>A>	+	AGOURON	EQ 625MG BASE	N21503 001	APR 30, 2003	APR	NEWA
		NITROFURANTOIN						
>D>		TABLET; ORAL						
>D>		FURADANTIN						
>D> AB		PROCTER AND GAMBLE	50MG	N08693 001		APR	DISC
>A>	@		50MG	N08693 001		APR	DISC
>D> AB	+		100MG	N08693 002		APR	DISC
>A>	@		100MG	N08693 002		APR	DISC
>D>		NITROFURANTOIN						
>D> AB		WATSON LAB	50MG	N80447 001		APR	DISC
>A>	@		50MG	N80447 001		APR	DISC
>D> AB		WHITEWORTH TOWN PLSN	100MG	N84085 002		APR	DISC
>A>	@		100MG	N84085 002		APR	DISC
		NITROFURAZONE						
		OINTMENT; TOPICAL						
		FURACIN						
	@	SHIRE PHARM	0.2%	N05795 001		MAR	DISC

NITROGLYCERIN
FILM, EXTENDED RELEASE; TRANSDERMAL*
NITROGLYCERIN

>D>	AB2	MYLAN	0.1MG/HR	N75033	001	FEB 06, 1998	APR	CAHN
>D>	AB2		0.2MG/HR	N74609	001	AUG 30, 1996	APR	CAHN
>D>	AB2		0.4MG/HR	N74607	001	AUG 30, 1996	APR	CAHN
>D>	AB2		0.6MG/HR	N74559	001	AUG 30, 1996	APR	CAHN
>A>	AB2	MYLAN TECHNOLOGIES	0.1MG/HR	N75033	001	FEB 06, 1998	APR	CAHN
>A>	AB2		0.2MG/HR	N74609	001	AUG 30, 1996	APR	CAHN
>A>	AB2		0.4MG/HR	N74607	001	AUG 30, 1996	APR	CAHN
>A>	AB2		0.6MG/HR	N74559	001	AUG 30, 1996	APR	CAHN

OINTMENT; TRANSDERMAL

>D>	+	ALTANA	2%	N87355	001	JUL 08, 1988	APR	CAHN
>A>	+	FOUGERA	2%	N87355	001	JUL 08, 1988	APR	CAHN

NIZATIDINE
CAPSULE; ORAL
NIZATIDINE

AB		TORPHARM	150MG	N76383	001	JAN 23, 2003	JAN	NEWA
AB			300MG	N76383	002	JAN 23, 2003	JAN	NEWA

NOREPINEPHRINE BITARTRATE
INJECTABLE; INJECTION
LEVOPHED

AP	+	ABBOTT	EQ 1MG BASE/ML	N07513	001		MAR	CFTG

NOREPINEPHRINE BITARTRATE

AP		GENSIA SICOR PHARMS	EQ 1MG BASE/ML	N40455	001	MAR 03, 2003	MAR	NEWA

NORETHINDRONE ACETATE
TABLET; ORAL
AYGESTIN

AB	+	WYETH PHARMS INC	5MG	N18405	001	APR 21, 1982	MAR	CAHN

NORGESTREL
TABLET; ORAL
OVRETTE

	+	WYETH PHARMS INC	0.075MG	N17031	001		MAR	CAHN

OMEPRAZOLE
CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB		LEK SVCS	10MG	N75757	001	JAN 28, 2003	JAN	NEWA
AB			20MG	N75757	002	JAN 28, 2003	JAN	NEWA

ORPHENADRINE CITRATE
INJECTABLE; INJECTION
ORPHENADRINE CITRATE

AP		BEDFORD LABS	30MG/ML	N40463	001	MAR 04, 2003	MAR	NEWA

* SEE SECTION 1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNIN
FILM, EXTENDED RELEASE; TRANSDERMAL
OXYTROL

		+	WATSON LABS (UTAH)	3.9MG/24HR	N21351 002	FEB 26, 2003	FEB	NEWA

PANTOPRAZOLE SODIUM
INJECTABLE; IV (INFUSION)
PROTONIX IV

		+	WYETH PHARMS INC	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	CAHN

TABLET, DELAYED RELEASE; ORAL
PROTONIX

>D>		+	WYETH PHARMS INC	EQ 20MG BASE	N20987 002	JUN 12, 2001	APR	CRLD
>A>				EQ 20MG BASE	N20987 002	JUN 12, 2001	APR	CRLD
		+		EQ 20MG BASE	N20987 002	JUN 12, 2001	MAR	CAHN
		+		EQ 40MG BASE	N20987 001	FEB 02, 2000	MAR	CAHN

PEGVISOMANT
INJECTABLE; SUBCUTANEOUS
SOMAVERT

		+	PHARMACIA AND UPJOHN	10MG/VIAL	N21106 001	MAR 25, 2003	MAR	NEWA
		+		15MG/VIAL	N21106 002	MAR 25, 2003	MAR	NEWA
		+		20MG/VIAL	N21106 003	MAR 25, 2003	MAR	NEWA

PERMETHRIN
CREAM; TOPICAL
PERMETHRIN

>A>	AB		CLAY PARK	5%	N76369 001	APR 21, 2003	APR	NEWA

PERPHENAZINE
TABLET; ORAL
PERPHENAZINE

	AB	+	IVAX PHARMS	16MG	N89457 001	SEP 10, 1987	FEB	CRLD

TRILAFON

		@	SCHERING	2MG	N10775 001		FEB	DISC
		@		4MG	N10775 002		FEB	DISC
		@		8MG	N10775 003		FEB	DISC
		@		16MG	N10775 004		FEB	DISC

PHENTERMINE HYDROCHLORIDE
CAPSULE; ORAL
PHENTERMINE HCL

	AA		ABLE	15MG	N40497 001	MAR 13, 2003	MAR	NEWA
	AA		AMIDE PHARM	15MG	N40460 001	JAN 14, 2003	JAN	NEWA
	AA			30MG	N40448 001	JAN 22, 2003	JAN	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SYRUP; ORAL
PHENERGAN VC

>D>	AA	+	WYETH AYERST	5MG/5ML;6.25MG/5ML	N08604 003	APR 02, 1984	APR	DISC
>A>		@		5MG/5ML;6.25MG/5ML	N08604 003	APR 02, 1984	APR	DISC

PROMETH VC PLAIN

>D>	AA		ALPHARMA	5MG/5ML;6.25MG/5ML	N88761 001	NOV 08, 1984	APR	CRLD

>A>	AA +		5MG/5ML;6.25MG/5ML	N88761 001	NOV 08, 1984	APR	CRLD

PHENYTOIN
SUSPENSION; ORAL
PHENYTOIN

	AB	VISTAPHARM	125MG/5ML	N40342 001	JAN 31, 2001	MAR	CAHN

PHENYTOIN SODIUM
INJECTABLE; INJECTION
DILANTIN

		@ PARKE DAVIS	50MG/ML	N10151 001		MAR	DISC

PHENYTOIN

	+	ELKINS SINN	50MG/ML	N84307 001		MAR	CRLD

PHENYTOIN SODIUM

		@ ABBOTT	50MG/ML	N89521 001	MAR 17, 1987	MAR	DISC
		@	50MG/ML	N89744 001	DEC 18, 1987	MAR	DISC

PHENYTOIN SODIUM, EXTENDED
CAPSULE; ORAL
DILANTIN

		PARKE DAVIS	30MG	N84349 001		FEB	CRLD

PILOCARPINE HYDROCHLORIDE
TABLET; ORAL
SALAGEN

>D>	+	MGI PHARMA INC	5MG	N20237 001	MAR 22, 1994	APR	CRLD
>A>			5MG	N20237 001	MAR 22, 1994	APR	CRLD
>A>	+		7.5MG	N20237 002	APR 18, 2003	APR	NEWA

PIPERACILLIN SODIUM
INJECTABLE; INJECTION
PIPRACIL

	+	WYETH PHARMS INC	EQ 2GM BASE/VIAL	N50545 002		MAR	CAHN
			EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	MAR	CAHN
	+		EQ 3GM BASE/VIAL	N50545 003		MAR	CAHN
			EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	MAR	CAHN
	+		EQ 4GM BASE/VIAL	N50545 004		MAR	CAHN
			EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	MAR	CAHN
	@		EQ 40GM BASE/VIAL	N50545 006	SEP 30, 1985	MAR	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
INJECTABLE; INJECTION
ZOSYN

	+	WYETH PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993	MAR	CAHN
	+		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993	MAR	CAHN
	+		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993	MAR	CAHN
	+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993	MAR	CAHN

ZOSYN IN PLASTIC CONTAINER

	+	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N50750 001	FEB 24, 1998	MAR	CAHN
	+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998	MAR	CAHN
	+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998	MAR	CAHN

		PRALIDOXIME CHLORIDE						
		INJECTABLE; INJECTION						
		PRALIDOXIME CHLORIDE						
		@ BAXTER HLTHCARE CORP	300MG/ML	N18799 001	DEC 13, 1982	MAR	CAHN
		PREDNICARBATE						
		CREAM; TOPICAL						
>A>		DERMATOP E EMOLLIENT						
>A>		+ DERMIK LABS	0.1%	N20279 001	OCT 29, 1993	APR	CTNA
>D>		DERMATOP						
>D>		+ DERMIK LABS	0.1%	N20279 001	OCT 29, 1993	APR	CTNA
		PREDNISOLONE						
		SYRUP; ORAL						
		PREDNISOLONE						
	AA	HI TECH PHARMA	15MG/5ML	N40401 001	FEB 27, 2003	FEB	NEWA
	AA	PHARM ASSOC	15MG/5ML	N40399 001	MAR 05, 2003	MAR	NEWA
		PREDNISOLONE SODIUM PHOSPHATE						
		SOLUTION; ORAL						
		PREDNISOLONE SODIUM PHOSPHATE						
	AA	HI TECH PHARMA	EQ 5MG BASE/5ML	N75183 001	MAR 26, 2003	MAR	NEWA
		PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM						
		SOLUTION/DROPS; OPHTHALMIC						
		SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE						
>A>	AT	ALCON	EQ 0.23% PHOSPHATE;10%	N73630 001	MAY 27, 1993	APR	CAHN
>D>	AT	ALCON UNIVERSAL	EQ 0.23% PHOSPHATE;10%	N73630 001	MAY 27, 1993	APR	CAHN
		PREDNISONE						
		TABLET; ORAL						
		PREDNISONE						
	AB	VINTAGE PHARMS	20MG	N40392 001	FEB 12, 2003	FEB	NEWA
		PROMETHAZINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
>D>		PHENERGAN						
>D>	AP	+ WYETH AYERST	50MG/ML	N08857 003		APR	DISC
>A>		@	50MG/ML	N08857 003		APR	DISC
		PROMETHAZINE HCL						
>D>	AP	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	APR	CRLD
>A>	AP	+	25MG/ML	N40454 001	AUG 22, 2002	APR	CRLD
>D>	AP		50MG/ML	N40454 002	AUG 22, 2002	APR	CRLD
>A>	AP	+	50MG/ML	N40454 002	AUG 22, 2002	APR	CRLD
	AP	PHARMAFORCE	25MG/ML	N40515 001	MAR 19, 2003	MAR	NEWA
		SUPPOSITORY; RECTAL						
		PHENERGAN						
	AB	+ WYETH AYERST	50MG	N11689 001		FEB	CTEC
	AB	WYETH PHARMS INC	12.5MG	N10926 002		MAR	CAHN
	AB	+	25MG	N10926 001		MAR	CAHN
	AB	+	50MG	N11689 001		MAR	CAHN
		PROMETHAZINE HCL						
>A>	AB	ABLE	12.5MG	N40504 001	APR 11, 2003	APR	NEWA

>A>	AB		25MG	N40504 002	APR 11, 2003	APR	NEWA
	AB		50MG	N40449 001	FEB 27, 2003	FEB	NEWA
	AB	G AND W LABS	12.5MG	N40428 002	MAR 31, 2003	MAR	NEWA
		TABLET; ORAL					
		PHENERGAN					
		WYETH PHARMS INC	12.5MG	N07935 002		MAR	CAHN
	BP		25MG	N07935 003		MAR	CAHN
	BP	+	50MG	N07935 004		MAR	CAHN
		PROPRANOLOL HYDROCHLORIDE					
		CAPSULE, EXTENDED RELEASE; ORAL					
		INDERAL LA					
		WYETH PHARMS INC	60MG	N18553 004	MAR 18, 1987	MAR	CAHN
	BX		80MG	N18553 002	APR 19, 1983	MAR	CTEC
	BX		120MG	N18553 003	APR 19, 1983	MAR	CTEC
		+	160MG	N18553 001	APR 19, 1983	MAR	CAHN
		INNOPRAN XL					
	BX	RELIANT PHARMS	80MG	N21438 001	MAR 12, 2003	MAR	NEWA
	BX		120MG	N21438 002	MAR 12, 2003	MAR	NEWA
		INJECTABLE; INJECTION					
		PROPRANOLOL HCL					
	AP	SABEX 2002	1MG/ML	N76400 001	FEB 26, 2003	FEB	NEWA
		TABLET; ORAL					
		INDERAL					
	AB	+ WYETH PHARMS INC	10MG	N16418 001		MAR	CAHN
	AB		20MG	N16418 003		MAR	CAHN
	AB		40MG	N16418 002		MAR	CAHN
	AB		60MG	N16418 009	OCT 18, 1982	MAR	CAHN
	AB	+	80MG	N16418 004		MAR	CAHN
		@	90MG	N16418 010	OCT 18, 1982	MAR	CAHN
		PYRIDOSTIGMINE BROMIDE					
		TABLET; ORAL					
		PYRIDOSTIGMINE BROMIDE					
>A>	AB	IMPAX LABS	60MG	N40502 001	APR 24, 2003	APR	NEWA
		@ US ARMY	30MG	N20414 001	FEB 05, 2003	FEB	NEWA
		QUETIAPINE FUMARATE					
		TABLET; ORAL					
		SEROQUEL					
		+ ASTRAZENECA	EQ 25MG BASE	N20639 001	SEP 26, 1997	MAR	CRLD
		QUINIDINE GLUCONATE					
		TABLET, EXTENDED RELEASE; ORAL					
		QUINAGLUTE					
		@ BERLEX LABS	324MG	N16647 001		MAR	DISC
		QUINIDINE GLUCONATE					
>D>	BX	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	APR	CRLD
>A>	BX	+	324MG	N89338 001	FEB 11, 1987	APR	CRLD
>D>		+ WATSON LABS	324MG	N87810 001	SEP 29, 1982	APR	CRLD
>A>	BX		324MG	N87810 001	SEP 29, 1982	APR	CRLD
		+	324MG	N87810 001	SEP 29, 1982	MAR	CRLD

QUINIDINE SULFATE
TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

AB	+	WYETH PHARMS INC	300MG	N12796 002			MAR	CAHN

RILUZOLE
TABLET; ORAL
RILUTEK

AB	+	AVENTIS	50MG	N20599 001	DEC 12, 1995		JAN	CFTG
		RILUZOLE						
AB		IMPAX LABS	50MG	N76173 001	JAN 29, 2003		JAN	NEWA

RIMANTADINE HYDROCHLORIDE
TABLET; ORAL
RIMANTADINE HCL

AB		AMIDE PHARM	100MG	N76375 001	JAN 14, 2003		JAN	NEWA

RISPERIDONE

>A>		TABLET, ORALLY DISINTEGRATING; ORAL						
>A>		RISPERDAL						
>A>		JOHNSON AND JOHNSON	0.5MG	N21444 001	APR 02, 2003		APR	NEWA
>A>	+		1MG	N21444 002	APR 02, 2003		APR	NEWA
>A>			2MG	N21444 003	APR 02, 2003		APR	NEWA

ROSIGLITAZONE MALEATE
TABLET; ORAL
AVANDIA

>D>		GLAXOSMITHKLINE	EQ 2MG BASE	N21071 002	MAY 25, 1999		APR	CAHN
>D>			EQ 4MG BASE	N21071 003	MAY 25, 1999		APR	CAHN
>D>	+		EQ 8MG BASE	N21071 004	MAY 25, 1999		APR	CAHN
>A>		SB PHARMCO	EQ 2MG BASE	N21071 002	MAY 25, 1999		APR	CAHN
>A>			EQ 4MG BASE	N21071 003	MAY 25, 1999		APR	CAHN
>A>	+		EQ 8MG BASE	N21071 004	MAY 25, 1999		APR	CAHN

SEVELAMER HYDROCHLORIDE
CAPSULE; ORAL
RENAGEL

>D>	+	GELTEX	403MG	N20926 001	OCT 30, 1998		APR	CAHN
>A>	+	GENZYME	403MG	N20926 001	OCT 30, 1998		APR	CAHN
		TABLET; ORAL						
>D>		GELTEX	400MG	N21179 001	JUL 12, 2000		APR	CAHN
>D>	+		800MG	N21179 002	JUL 12, 2000		APR	CAHN
>A>		GENZYME	400MG	N21179 001	JUL 12, 2000		APR	CAHN
>A>	+		800MG	N21179 002	JUL 12, 2000		APR	CAHN

SIROLIMUS
SOLUTION; ORAL
RAPAMUNE

	+	WYETH PHARMS INC	1MG/ML	N21083 001	SEP 15, 1999		MAR	CAHN
		TABLET; ORAL						
		WYETH PHARMS INC	1MG	N21110 001	AUG 25, 2000		MAR	CRLD
	+		2MG	N21110 002	AUG 22, 2002		MAR	NEWA

		SODIUM IODIDE, I-131						
		CAPSULE; ORAL						
		SODIUM IODIDE I 131						
	+	DRAXIMAGE	1-250mCi	N21305 002	JAN 24, 2003	JAN	NEWA	
	+		1-500mCi	N21305 003	JAN 24, 2003	JAN	NEWA	
		SOLUTION; ORAL						
		SODIUM IODIDE I 131, KIT						
	+	DRAXIMAGE	1-250mCi/0.25ML	N21305 002	JAN 24, 2003	FEB	CDFR	
	+		1-500mCi/0.5ML	N21305 003	JAN 24, 2003	FEB	CDFR	
		SOMATROPIN RECOMBINANT						
		INJECTABLE; INJECTION						
		BIO-TROPIN						
	@	BIO TECH GEN	4.8MG/VIAL	N19774 001	MAY 25, 1995	MAR	DISC	
		TEV-TROPIN						
BX	+	BIO TECH GEN	5MG/ML	N19774 002	JAN 04, 2002	FEB	CTNA	
		SOTALOL HYDROCHLORIDE						
		TABLET; ORAL						
		BETAPACE AF						
>A>		BERLEX LABS	40MG	N21151 006	APR 02, 2003	APR	NEWA	
>A>			60MG	N21151 007	APR 02, 2003	APR	NEWA	
			100MG	N21151 005	MAR 14, 2003	MAR	NEWA	
		STRONTIUM CHLORIDE, SR-89						
		INJECTABLE; INJECTION						
		METASTRON						
AP	+	AMERSHAM HLTH	1mCi/ML	N20134 001	JUN 18, 1993	JAN	CFTG	
		STRONTIUM CHLORIDE SR-89						
AP		BIO NUCLEONICS	1mCi/ML	N75941 001	JAN 06, 2003	JAN	NEWA	
		TAMOXIFEN CITRATE						
		TABLET; ORAL						
		NOLVADEX						
AB		ASTRAZENECA	EQ 10MG BASE	N17970 001		FEB	CTEC	
AB	+		EQ 20MG BASE	N17970 002	MAR 21, 1994	FEB	CTEC	
		TAMOXIFEN CITRATE						
AB		AEGIS PHARMS	EQ 10MG BASE	N76398 001	MAR 31, 2003	MAR	NEWA	
AB			EQ 20MG BASE	N76398 002	MAR 31, 2003	MAR	NEWA	
AB		ANDRX PHARMS	EQ 10MG BASE	N76179 001	FEB 20, 2003	FEB	NEWA	
AB			EQ 20MG BASE	N76179 002	FEB 20, 2003	FEB	NEWA	
AB		BARR	EQ 10MG BASE	N70929 001	FEB 20, 2003	FEB	NEWA	
AB			EQ 20MG BASE	N70929 002	FEB 20, 2003	FEB	NEWA	
AB		IVAX PHARMS	EQ 10MG BASE	N75740 001	FEB 20, 2003	FEB	NEWA	
AB			EQ 20MG BASE	N75740 002	FEB 20, 2003	FEB	NEWA	
AB		MYLAN	EQ 10MG BASE	N74732 002	FEB 20, 2003	FEB	NEWA	
AB			EQ 20MG BASE	N74732 001	FEB 20, 2003	FEB	NEWA	
>A> AB		PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAR 31, 2003	APR	CAHN	
AB			EQ 20MG BASE	N74858 001	FEB 20, 2003	FEB	NEWA	
AB		ROXANE	EQ 10MG BASE	N76027 001	FEB 20, 2003	FEB	NEWA	
AB			EQ 20MG BASE	N76027 002	FEB 20, 2003	FEB	NEWA	
>A> AB		TEVA	EQ 10MG BASE	N74504 001	APR 28, 2003	APR	NEWA	

>D>	AB		EQ 10MG BASE	N74539 001	MAR 31, 2003	APR	CAHN
	AB		EQ 10MG BASE	N74539 001	MAR 31, 2003	MAR	NEWA
	AB		EQ 10MG BASE	N75797 001	FEB 20, 2003	FEB	NEWA
>A>	AB		EQ 20MG BASE	N74504 002	APR 28, 2003	APR	NEWA
		TECHNETIUM TC-99M MEDRONATE KIT					
		INJECTABLE; INJECTION					
		TECHNESCAN MDP KIT					
	AP	+ DRAXIMAGE	N/A	N18035 001		MAR	CRLD
		TESTOSTERONE					
		GEL; TOPICAL					
		ANDROGEL					
>D>		+ UNIMED PHARMS	1%	N21015 001	FEB 28, 2000	APR	CTEC
>A>	BX	+	1%	N21015 001	FEB 28, 2000	APR	CTEC
		TESTIM					
>D>		+ AUXILIUM A2	1%	N21454 001	OCT 31, 2002	APR	CTEC
>A>	BX	+	1%	N21454 001	OCT 31, 2002	APR	CTEC
		THALIDOMIDE					
		CAPSULE; ORAL					
		THALOMID					
		CELGENE	100MG	N20785 002	JAN 17, 2003	JAN	NEWA
		+	200MG	N20785 003	JAN 17, 2003	JAN	NEWA
		THIOTHIXENE					
		CAPSULE; ORAL					
		NAVANE					
	AB	PFIZER	1MG	N16584 001		FEB	CAHN
	AB		2MG	N16584 002		FEB	CAHN
	AB	+	5MG	N16584 003		FEB	CAHN
	AB		10MG	N16584 004		FEB	CAHN
			20MG	N16584 005		FEB	CAHN
		THIOTHIXENE HYDROCHLORIDE					
		CONCENTRATE; ORAL					
	AA	+ PFIZER	EQ 5MG BASE/ML	N16758 001		FEB	CAHN
		INJECTABLE; INJECTION					
		@ PFIZER	EQ 2MG BASE/ML	N16904 001		FEB	CAHN
		+	EQ 10MG BASE/VIAL	N16904 002		FEB	CAHN
		TIZANIDINE HYDROCHLORIDE					
		TABLET; ORAL					
		TIZANIDINE HCL					
>A>	AB	BARR	EQ 2MG BASE	N76371 001	APR 09, 2003	APR	NEWA
>A>	AB		EQ 4MG BASE	N76371 002	APR 09, 2003	APR	NEWA
	AB	MYLAN	EQ 2MG BASE	N76354 001	MAR 28, 2003	MAR	NEWA
	AB		EQ 4MG BASE	N76354 002	MAR 28, 2003	MAR	NEWA
		TRAMADOL HYDROCHLORIDE					
		TABLET; ORAL					
		TRAMADOL HCL					
	AB	IVAX PHARMS	50MG	N75963 001	JUL 03, 2002	MAR	CAHN

TRIAMCINOLONE ACETONIDE
LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

>A>	AT	ALTANA	0.025%	N40467	001	APR 21, 2003	APR	NEWA
>A>	AT		0.1%	N40467	002	APR 21, 2003	APR	NEWA

UREA, C-13
FOR SOLUTION; ORAL
PYLORI-CHEK BREATH TEST

		@ DEVICES	100MG/VIAL	N20900	001	FEB 04, 1999	MAR	CAHN

VENLAFAXINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR

		WYETH PHARMS INC	EQ 37.5MG BASE	N20699	001	OCT 20, 1997	MAR	CAHN
			EQ 75MG BASE	N20699	002	OCT 20, 1997	MAR	CRLD
		@	EQ 100MG BASE	N20699	003	OCT 20, 1997	MAR	CAHN
		+	EQ 150MG BASE	N20699	004	OCT 20, 1997	MAR	CRLD

TABLET; ORAL
EFFEXOR

		@ WYETH PHARMS INC	EQ 12.5MG BASE	N20151	001	DEC 28, 1993	MAR	CAHN
			EQ 25MG BASE	N20151	002	DEC 28, 1993	MAR	CRLD
			EQ 37.5MG BASE	N20151	006	DEC 28, 1993	MAR	CAHN
			EQ 50MG BASE	N20151	003	DEC 28, 1993	MAR	CAHN
			EQ 75MG BASE	N20151	004	DEC 28, 1993	MAR	CAHN
		+	EQ 100MG BASE	N20151	005	DEC 28, 1993	MAR	CAHN

VINORELBINE TARTRATE
INJECTABLE; INJECTION
NAVELBINE

AP	+	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N20388	001	DEC 23, 1994	FEB	CFTG

VINORELBINE TARTRATE

AP		GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N76028	001	FEB 03, 2003	FEB	NEWA

ZOLEDRONIC ACID
INJECTABLE; IV (INFUSION)
ZOMETA

	+	NOVARTIS	EQ 4MG BASE/5ML	N21223	002	MAR 07, 2003	MAR	NEWA

	ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE						
	TABLET, CHEWABLE; ORAL						
	FOAMICON						
	NOVARTIS	80MG;20MG	N72687	001	JUN 28, 1989	MAR	CAHN
	CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE						
	CAPSULE, EXTENDED RELEASE; ORAL						
	PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE						
	@ CENT PHARMS	8MG;120MG	N19428	001	AUG 02, 1988	MAR	DISC
	CIMETIDINE						
	TABLET; ORAL						
	CIMETIDINE						
	@ LEK PHARMS	100MG	N75122	001	JUN 19, 1998	MAR	CAHN
		200MG	N75122	002	JUN 19, 1998	MAR	CAHN
	GUAIFENESIN						
	TABLET, EXTENDED RELEASE; ORAL						
	MUCINEX						
	ADAMS LABS	600MG	N21282	001	JUL 12, 2002	JAN	CRLD
+		1.2GM	N21282	002	DEC 18, 2002	JAN	NEWA
	LOPERAMIDE HYDROCHLORIDE; SIMETHICONE						
	TABLET; ORAL						
	IMODIUM ADVANCED						
+	MCNEIL CONS SPECLT	2MG;125MG	N21140	001	NOV 30, 2000	JAN	CRLD
	LORATADINE						
	SYRUP; ORAL						
	CLARITIN						
>D>	SCHERING	1MG/ML	N20641	002	NOV 27, 2002	APR	CRLD
>A> +		1MG/ML	N20641	002	NOV 27, 2002	APR	CRLD
		1MG/ML	N20641	002	NOV 27, 2002	MAR	NEWA
	TABLET; ORAL						
>D>	SCHERING	10MG	N19658	002	NOV 27, 2002	APR	CRLD
>A> +		10MG	N19658	002	NOV 27, 2002	APR	CRLD
		10MG	N19658	002	NOV 27, 2002	MAR	NEWA
	LORATADINE						
	GENEVA PHARMS	10MG	N75209	001	JAN 21, 2003	JAN	NEWA
	TABLET, ORALLY DISINTEGRATING; ORAL						
	ALAVERT						
>D> +	WYETH CONS	10MG	N21375	001	DEC 19, 2002	APR	CRLD
>A>		10MG	N21375	001	DEC 19, 2002	APR	CRLD
	CLARITIN REDITABS						
>D>	SCHERING	10MG	N20704	002	NOV 27, 2002	APR	CRLD
>A> +		10MG	N20704	002	NOV 27, 2002	APR	CRLD
		10MG	N20704	002	NOV 27, 2002	MAR	NEWA
	LORATADINE						
	WYETH CONS	10MG	N75822	001	FEB 10, 2003	FEB	NEWA

	LORATADINE; PSEUDOEPHEDRINE SULFATE							
	TABLET, EXTENDED RELEASE; ORAL							
	CLARITIN-D							
>D>	SCHERING	5MG;120MG	N19670	002	NOV 27, 2002	APR	CRLD	
>A>	+	5MG;120MG	N19670	002	NOV 27, 2002	APR	CRLD	
		5MG;120MG	N19670	002	NOV 27, 2002	MAR	NEWA	
	CLARITIN-D 24 HOUR							
>D>	SCHERING	10MG;240MG	N20470	002	NOV 27, 2002	APR	CRLD	
>A>	+	10MG;240MG	N20470	002	NOV 27, 2002	APR	CRLD	
		10MG;240MG	N20470	002	NOV 27, 2002	MAR	NEWA	
	LORATADINE AND PSEUDOEPHEDRINE HCL							
	ANDRX PHARMS	10MG;240MG	N75706	001	FEB 21, 2003	FEB	NEWA	
	LORATADINE AND PSEUDOEPHEDRINE SULFATE							
	IMPAX LABS	5MG;120MG	N76050	001	JAN 30, 2003	JAN	NEWA	
	MINOXIDIL							
	SOLUTION; TOPICAL							
	MINOXIDIL EXTRA STRENGTH (FOR MEN)							
	MORTON GROVE	5%	N75438	001	FEB 27, 2003	FEB	NEWA	
	PERMETHRIN							
	LOTION; TOPICAL							
	NIX							
+	INSIGHT PHARMS	1%	N19918	001	MAY 02, 1990	MAR	CAHN	

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL '03

NO APRIL 2003 APPROVALS

This data is provided to the Office of Generic Drugs from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
April 2003

Generic Name/ Trade Name (if present):	Date Designated = DD Date Approved= MA	Indication Designated:	Sponsor and Address
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003 MA:	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	BioMedicines, Inc. 2000 Powell Street Suite 1640 Emeryville CA 94608
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003 MA:	Treatment of mitochondrial disease	Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham MA 02453
4,5-dibromorhodamine 123 Theralux Irradiation Device	DD: 4/10/2003 MA:	Treatment of chronic myelogenous leukemia	Celmed BioSciences Inc. 2310 boul Alfred-Nobel 2310 boul Alfred-Nobel Saint-Laurent, Quebec Canada H4S 2A4
a-(3-aminophthalimido) Actimid	DD: 1/15/2003 MA: MA:	Treatment of multiple myeloma	Celgene Corporation 7 Powder Horn Drive Warren NJ 07059
a-Galactosidase A Plant-Produced Human a-Glactosidase	DD: 1/21/2003 MA:	Treatment of Fabry's disease	Large Scale Biology Corporation 3333 Vacaville Parkway Suite 1000 Vacaville CA 95688
alendronate Fosamax	DD: 3/31/2003 MA:	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
alteplase Activase	DD: 1/27/2003 MA:	Treatment of intraventricular hemmorage associated with intracerebral hemmorrhage	Daniel F. Hanley, MD Johns Hopkins University Johns Hopkins University 600 N. Wolfe St., Jefferson 1-109 Baltimore MD 21287
AMG 531	DD: 3/27/2003 MA:	Treatment of immune thrombocytopenic purpura.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
anti-CD23 IgG1, kappa monoclonal antibody	DD: 2/12/2003 MA:	Treatment of chronic lymphocytic leukemia	IDEC Pharmaceuticals, Inc. 3030 Callan Road San Diego CA 92121

Orphan Products Designations and Approvals List

April 2003

antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] GTI-2040	DD: 3/12/2003 MA: MA:	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc 2 Meridan Road Toronto, Ontario M9W427 CANADA
arsenic trioxide Trisenox	DD: 5/13/2003 MA:	Treatment of chronic lymphocytic leukemia	Cell Therapeutics, Inc. 501 Elliott avenue West 501 Elliott avenue West Suite 400 Seattle WA 98119
bifidobacterium longum infantis 35624	DD: 1/16/2003 MA:	Treatment of pediatric Crohn's disease	Alimentary Health Limited Guardwell, Kinsale County Cork, Ireland
bortezomib VELCADE	DD: 1/15/2003 MA:	To treat multiple myeloma	Millennium Pharmaceuticals, Inc. 75 Sidney Street Cambridge MA 02139
Capsaicin	DD: 5/2/2003 MA:	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc. San Carlos Business Park 981F Industrial Road San Carols CA 94070-4117
cinacalcet	DD: 5/12/2003 MA:	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
dextran 1	DD: 3/21/2003 MA:	Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600 Toronto, Ontario M4P 3B5
DHA-paclitaxel Taxoprexin	DD: 5/1/2003 MA:	Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance Boulevard 2200 Renaissance Boulevard Suite 450 King of Prussia PA 19406
Human Anti-tumor Necrosis factor alpha monoclonal antibody	DD: 1/16/2003 MA:	Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
infliximab Remicade	DD: 5/6/2003 MA:	Treatment of giant cell arteritis	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
INGN 201 ADVEXIN	DD: 1/27/2003 MA: MA:	Treatment of head and neck cancer	Introgen Therapeutics, Inc. 2250 Holcombe Blvd

Orphan Products Designations and Approvals List

April 2003

			Houston TX 77030
iron(III)-hexacyanoferrate(II)	DD: 5/1/2003	Treatment of patients with known or susupected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG Goerzallee 253
Radiogardase-Cs / Antidotum	MA: MA:		Goerzallee 253 D-14167 Berlin, Federal Republic of Germany
Mafosfamide	DD: 1/21/2003	Treatment of neoplastic meningitis	Baxter Oncology GmbH (formerly ASTA Medica Oncology) Daimlerstrasse 40
	MA:		60314 franfurt/Main Germany
MaxAdFVIII	DD: 3/3/2003	Treatment of Hemophilia A	GenStar Theraeutics Corporation 10865 Altman Row
	MA:		Suite 200 San Diego CA 92121-1113
motexafin gadolinium	DD: 1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc. 999 East Arques Avenue
Xcytrin	MA:		999 East Arques Avenue
	MA:		Sunnyvale CA 94085-4521
polyinosinic-polycytidilic acid	DD: 3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Ribopharm, Inc. 3203 Cleveland Ave., NW
Poly-ICLC	MA:		3203 Cleveland Ave., NW
	MA:		Washington DC 20008-3450
recombinant adeno-associated virus alpha 1-antitrypsin vector rAAV-AAT	DD: 1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp. 12085 Research Drive
	MA:		
	MA:		Suite 110 Alachua FL 32615
recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003	Treatment of angioedema	Dyax Corp 300 Technology Square
	MA:		Cambridge MA 02139
Recombinant T-cell receptor	DD: 5/2/2003	Treatment of mutliple sclerosis patients who are both HLA-DR2 positive and glycoprotein residues 35-55 autoreactive to myelin oligodendrocyte	Virogenomics, Inc. 9020 SW Washington Square Road
	MA:		Suite 380
	MA:		Tigard, OR 97223-4332
repertaxin	DD: 1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile
	MA:		67100 - L'Aquila Italy
resiniferatoxin	DD: 5/13/2003	Treatment of intractable pain at end-stage disease	Andrew J. Mannes, Md Bldg 10/Rm 2N236 - DASS/PPCS/NIDCR/NIH
	MA:		10 Convent Drive Bethesda MD 20892
Ribavirin USP	DD: 4/4/2003	Treatment of chronic hepatitis C in	Schering Corporation

Orphan Products Designations and Approvals List

April 2003

REBETOL		pediatric patients	2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
	MA:		
Sodium pyruvate	DD: 3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc. 84 Park Avenue P. O. Box 968 Flemington NJ 08822
	MA:		
Tezacitabine	DD: 1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916
	MA:		
Tretinoin ATRA-IV	DD: 4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc. 34 Commerce Way 34 Commerce Way Woburn MA 01801
	MA:		

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 2003 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020977 001	ABACAVIR SULFATE;ZIAGEN	5034394	DEC 18, 2011			
>ADD>			5034394*PED	JUN 18, 2012			
>ADD>	020978 001	ABACAVIR SULFATE;ZIAGEN	5034394	DEC 18, 2011			
>ADD>			5034394*PED	JUN 18, 2012			
	020213 001	ACETYLCHOLINE CHLORIDE;MIOCHOL-E	6261546	APR 29, 2019	U-506		
	020899 001	ALBUMIN HUMAN;OPTISON	5573751	APR 25, 2012			
			5529766	JUN 25, 2013	U-505		
			5558094	FEB 28, 2012	U-505		
>ADD>	020560 001	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		I-309	SEP 29, 2003
>ADD>			4621077	AUG 06, 2007	U-114	PED	MAR 29, 2004
>ADD>			5681590	DEC 02, 2012			
>ADD>			5849726	JUN 06, 2015			
>ADD>			6008207	JUN 06, 2015	U-303		
>ADD>			6090410	DEC 02, 2012			
>ADD>			6194004	DEC 02, 2012			
>ADD>			4621077*PED	FEB 06, 2008	U-114		
>ADD>			5358941*PED	JUN 02, 2013			
>ADD>			5681590*PED	JUN 02, 2013			
>ADD>			5849726*PED	DEC 06, 2015			
>ADD>			6008207*PED	DEC 06, 2015	U-303		
>ADD>			6090410*PED	JUN 02, 2013			
>ADD>			6194004*PED	JUN 02, 2013			
>ADD>	020560 002	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012			
>ADD>			4621077	AUG 06, 2007	U-114		
>ADD>			5681590	DEC 02, 2012			
>ADD>			5849726	JUN 06, 2015			
>ADD>			6008207	JUN 06, 2015	U-303		
>ADD>			6090410	DEC 02, 2012			
>ADD>			4621077*PED	FEB 06, 2008	U-114		
>ADD>			5358941*PED	JUN 02, 2013			
>ADD>			5681590*PED	JUN 02, 2013			
>ADD>			5849726*PED	DEC 06, 2015			
>ADD>			6008207*PED	JUN 06, 2015	U-303		
>ADD>			6090410*PED	JUN 02, 2013			
>ADD>	020560 003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012			
>ADD>			4621077	AUG 06, 2007	U-114		
>ADD>			5681590	DEC 02, 2012			
>ADD>			5849726	JUN 06, 2015			
>ADD>			6008207	JUN 06, 2015	U-303		
>ADD>			6090410	DEC 02, 2012			
>ADD>			4621077*PED	FEB 06, 2008	U-114		
>ADD>			5358941*PED	JUN 02, 2013			
>ADD>			5681590*PED	JUN 02, 2013			
>ADD>			5849726*PED	DEC 06, 2015			
>ADD>			6008207*PED	DEC 06, 2015	U-303		
>ADD>			6090410*PED	JUN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020560 004	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
>ADD>			4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
>ADD>			5358941	DEC 02, 2012		D-62	OCT 20, 2003
>ADD>			5681590	DEC 02, 2012		PED	APR 20, 2004
>ADD>			5849726	JUN 06, 2015		PED	APR 20, 2004
>ADD>			6008207	JUN 06, 2015		PED	APR 20, 2004
>ADD>			6090410	DEC 02, 2012			
>ADD>			5994329	JUL 17, 2018			
>ADD>			6225294	JUL 17, 2018			
>ADD>			4621077*PED	FEB 06, 2008	U-114		
>ADD>			5358941*PED	JUN 02, 2013			
>ADD>			5681590*PED	JUN 02, 2013			
>ADD>			5849726*PED	DEC 16, 2015			
>ADD>			5994329*PED	JAN 17, 2019			
>ADD>			6008207*PED	DEC 06, 2015			
>ADD>			6015801*PED	JAN 17, 2019	U-353		
>ADD>			6090410*PED	JUN 02, 2013			
>ADD>			6225294*PED	JAN 17, 2019			
>ADD>	020560 005	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
>ADD>			4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
>ADD>			5358941	DEC 02, 2012		D-62	OCT 20, 2003
>ADD>			5681590	DEC 02, 2012		PED	APR 20, 2004
>ADD>			5849726	JUN 06, 2015		PED	APR 20, 2004
>ADD>			5994329	JUL 17, 2018		PED	APR 20, 2004
>ADD>			6008207	JUN 06, 2015			
>ADD>			6090410	DEC 02, 2012			
>ADD>			6225294	JUL 17, 2018			
>ADD>			4621077*PED	FEB 06, 2008	U-114		
>ADD>			5358941*PED	JUN 02, 2013			
>ADD>			5681590*PED	JUN 02, 2013			
>ADD>			5849726*PED	DEC 06, 2015			
>ADD>			5994329*PED	JAN 17, 2019			
>ADD>			6008207*PED	DEC 06, 2015			
>ADD>			6015801*PED	JAN 17, 2019	U-353		
>ADD>			6090410*PED	JUN 02, 2013			
>ADD>			6225294*PED	JAN 17, 2019			
	021434 001	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
	021434 002	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
	021434 003	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
	021434 004	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
	020221 002	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012			
	020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	5954703	OCT 31, 2017	U-289		
	021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	OCT 21, 2018			
	021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819	OCT 21, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	OCT 21, 2018			
	021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819	OCT 21, 2018			
	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	OCT 21, 2018			
	021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	OCT 21, 2018			
	040422 005	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
	040422 006	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
	040422 007	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE				PC	SEP 15, 2003
>ADD>	021549 001	APREPITANT;EMEND	5719147	JUN 29, 2012		NCE	MAR 26, 2008
>ADD>			5538982	JUL 23, 2013			
>ADD>			6048859	JUN 29, 2012			
>ADD>			6096742	JUL 01, 2018			
>ADD>			6235735	JUN 29, 2012			
>ADD>	021549 002	APREPITANT;EMEND	5719147	JUN 29, 2012		NCE	MAR 26, 2008
>ADD>			5538982	JUL 23, 2013			
>ADD>			6048859	JUN 29, 2012			
>ADD>			6096742	JUL 01, 2018			
>ADD>			6235735	JUN 29, 2012			
	021436 001	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 002	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 003	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 004	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 005	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021436 006	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005			
			5006528	OCT 20, 2009			
	021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494	NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494	PED	MAY 26, 2008
	075766 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	075766 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
>ADD>	075823 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	075823 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	075836 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	075836 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
	020637 001	CARMUSTINE;GLIADEL	4789724	AUG 01, 2006		I-382	FEB 25, 2006
			4757128	AUG 01, 2006			
>ADD>	020297 001	CARVEDILOL;COREG				I-388	MAR 27, 2006
>ADD>	020297 002	CARVEDILOL;COREG				I-388	MAR 27, 2006
>ADD>	020297 003	CARVEDILOL;COREG				I-388	MAR 27, 2006
>ADD>	020297 004	CARVEDILOL;COREG				I-388	MAR 27, 2006
	021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	4525358	JUN 25, 2007	U-295		
			4525358*PED	DEC 25, 2007	U-295		
			6469009	JUL 13, 2019	U-295		
			6469009*PED	JAN 13, 2020	U-295		
			6489329	APR 08, 2016			
			6489329*PED	OCT 08, 2016			
>ADD>	021159 001	CICLOPIROX;LOPROX				NDF	FEB 28, 2006
>ADD>	021473 001	CIPROFLOXACIN;CIPRO XR	4670444	DEC 09, 2003		NDF	DEC 13, 2005
	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	6504030	JUN 10, 2019			
	019758 001	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
	019758 002	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6066678	JUN 10, 2014	U-323		
	017821 001	CYCLOBENZAPRINE HYDROCHLORIDE;FLEXERIL				D-78	FEB 03, 2006
	021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
			4863931	SEP 15, 2008		PED	JUN 21, 2007
			4804666	FEB 14, 2006	U-428		
			5595997	DEC 30, 2014	U-429		
			6100274	JUL 07, 2019			
			4659716*PED	OCT 21, 2004	U-427		
			4804666*PED	AUG 14, 2006	U-428		
			4863931*PED	MAR 15, 2009			
			5595997*PED	JUN 30, 2015	U-429		
			6100274*PED	JAN 07, 2020			
	021312 001	DESLORATADINE;CLARINEX				NCE	DEC 21, 2006
						PED	JUN 21, 2007
>ADD>	021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
>ADD>			5529791	JUN 25, 2013			
>ADD>	021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
>ADD>			5529791	JUN 25, 2013			
>ADD>	021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
>ADD>			5529791	JUN 25, 2013			
>ADD>	021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
>ADD>			5529791	JUN 25, 2013			
>ADD>	021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
>ADD>			5529791	JUN 25, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
>ADD>			5529791	JUN 25, 2013			
	020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6511678	DEC 18, 2018			
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6511678	DEC 18, 2018			
>ADD>	020941 001	DOCOSANOL;ABREVA	4874794	APR 28, 2014			
	021360 001	EFAVIRENZ;SUSTIVA	5663169	SEP 02, 2014			
	021481 001	ENFUVIRTIDE;FUZEON	5464933	JUN 07, 2013		NCE	MAR 13, 2008
			6133418	JUN 07, 2013			
			6475491	JUN 07, 2015	U-248		
	021437 001	EPLERENONE;INSPRA	6534093	DEC 08, 2019	U-3		
	021437 002	EPLERENONE;INSPRA	6534093	DEC 08, 2019	U-3		
	021437 003	EPLERENONE;INSPRA	6534093	DEC 08, 2019	U-3		
>ADD>	019386 004	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
>ADD>			6310094	JAN 12, 2021			
			6528540	JAN 12, 2021			
>ADD>	019386 006	ESMOLOL HYDROCHLORIDE;BREVIBLOC	4593119	JUN 03, 2003			
>ADD>			6310094	JAN 12, 2021			
			6528540	JAN 12, 2021			
>ADD>	019386 005	ESMOLOL HYDROCHLORIDE;BREVIBLOC DOUBLE STR	4593119	JUN 03, 2003			
>ADD>			6310094	JAN 12, 2021			
			6528540	JAN 12, 2021			
>ADD>	021367 001	ESTRADIOL ACETATE;FEMRING	5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
>ADD>	021367 002	ESTRADIOL ACETATE;FEMRING	5855906	DEC 19, 2015	U-508	NP	MAR 20, 2006
>ADD>	021180 001	ETHINYL ESTRADIOL;ORTHO EVRA	5876746	JUN 07, 2015			
>ADD>			5972377	JUN 07, 2015			
	020747 001	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 002	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 003	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 004	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 005	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	020747 006	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006			
			5785989	SEP 05, 2006			
	019813 001	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
			4588580*PED	JAN 23, 2005	U-43		
	019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
			4588580*PED	JAN 23, 2005	U-43		
	019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
			4588580*PED	JAN 23, 2005	U-43		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43		
		4588580*PED	JAN 23, 2005	U-43		
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-192		
		5855912	FEB 28, 2015			
		5738872	FEB 28, 2015			
		5932247	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014	U-192		
		5738872*PED	AUG 28, 2015			
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014	U-139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014	U-139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014	U-139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	5578610	NOV 26, 2013			
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014			
		5855912*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6039974*PED	JAN 31, 2019			
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		
020038 001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
		4357324*PED	AUG 24, 2003			
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387	PED	FEB 24, 2004
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
		4335121*PED	MAY 14, 2004			
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387	PED	FEB 24, 2004
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
		4335121*PED	MAY 14, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387	PED	FEB 24, 2004
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
		4335121*PED	MAY 14, 2004			
019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121	NOV 14, 2003		D-76	MAY 23, 2005
		4335121*PED	MAY 14, 2004		PED	NOV 23, 2005
020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020261 001	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
020261 002	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-413		
		5354772	OCT 11, 2011	U-109		
021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413		
		5354772	OCT 11, 2011	U-413		
		5354772	OCT 11, 2011	U-109		
020831 001	FORMOTEROL FUMARATE;FORADIL	6488027	MAR 08, 2019		I-342	SEP 25, 2004
019915 002	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			
019915 003	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019915 004	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
			5006344	JUL 10, 2009			
			5006344*PED	JAN 10, 2010			
			4337201*PED	JUN 04, 2003			
	020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
			5006344	JUL 10, 2009			
			5006344*PED	JAN 10, 2010			
			4337201*PED	JUN 04, 2003			
	020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
			5006344	JUL 10, 2009			
			5006344*PED	JAN 10, 2010			
			4337201*PED	JUN 04, 2003			
>ADD>	021493 001	GATIFLOXACIN;ZYMAR				NDF	MAR 28, 2006
>ADD>						NCE	DEC 17, 2004
>ADD>	021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6262071	SEP 21, 2019		NCE	APR 04, 2008
			6331550	SEP 21, 2019			
			6340689	SEP 14, 2019			
			6455540	SEP 21, 2019			
	020329 001	GLIPIZIDE;GLUCOTROL XL	5091190	SEP 05, 2009	U-111		
			5545413	JUL 21, 2008	U-111		
	020329 002	GLIPIZIDE;GLUCOTROL XL	5091190	SEP 05, 2009	U-111		
			5545413	JUL 21, 2008	U-111		
	020329 003	GLIPIZIDE;GLUCOTROL XL	4612008	SEP 16, 2003			
			5024843	SEP 05, 2009			
			5082668	SEP 16, 2003			
			5091190	SEP 05, 2009	U-111		
			5545413	JUL 21, 2008	U-111		
			5591454	JAN 07, 2014	U-111		
	021282 002	GUAIFENESIN;MUCINEX	6372252	APR 28, 2020	U-489		
	021321 001	ICODEXTRIN;EXTRANEAL	6248726	JUN 19, 2018	U-495		
			4761237	AUG 02, 2005	U-495		
			4886789	DEC 12, 2006	U-495		
			6077836	JUN 20, 2017	U-495		
>ADD>	021588 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
>ADD>	021588 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
	021425 001	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	U-498		
	021425 002	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	U-498		
	020857 001	LAMIVUDINE;COMBIVIR	5047407*PED	MAY 17, 2010			
			5047407	NOV 17, 2009			
	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	NOV 17, 2009			
			5047407*PED	MAY 17, 2010			
	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	NOV 17, 2009			
			5047407*PED	MAY 17, 2010			
>ADD>	020241 001	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020241 002	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
>ADD>	020241 003	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
>ADD>	020241 004	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
>ADD>	020241 005	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
>ADD>	020241 006	LAMOTRIGINE;LAMICTAL				I-387	JAN 17, 2006
>ADD>	020764 001	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
>ADD>	020764 002	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
>ADD>	020764 003	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
>ADD>	020764 004	LAMOTRIGINE;LAMICTAL CD				I-387	JAN 17, 2006
	021488 001	LEUPROLIDE ACETATE;ELIGARD				NP	FEB 13, 2006
>ADD>	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
>ADD>	021301 001	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 002	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 003	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 004	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 005	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 006	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 007	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 008	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 009	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 010	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 011	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
>ADD>	021301 012	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
	020612 001	LIDOCAINE;LIDODERM	5589180	MAR 17, 2009	U-485		
			5411738	MAY 02, 2012			
			5827529	OCT 27, 2015	U-486		
			5709869	MAR 17, 2009	U-485		
			5601838	MAY 02, 2012	U-488		
	021130 001	LINEZOLID;ZYVOX				NPP	DEC 19, 2005
	021130 002	LINEZOLID;ZYVOX				NPP	DEC 19, 2005
	021131 001	LINEZOLID;ZYVOX				NPP	DEC 19, 2005
	021132 001	LINEZOLID;ZYVOX				NPP	DEC 19, 2005
	021226 001	LOPINAVIR;KALETRA	6521651	NOV 01, 2017			
	075209 001	LORATADINE;LORATADINE				PC	JUL 21, 2003
>ADD>	075822 001	LORATADINE;LORATADINE				PC	AUG 09, 2003
	076050 001	LORATADINE;LORATADINE AND PSEUD				PC	JUL 30, 2003
	020386 001	LOSARTAN POTASSIUM;COZAAR	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	020386 002	LOSARTAN POTASSIUM;COZAAR	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	020386 003	LOSARTAN POTASSIUM;COZAAR	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
	076119 001	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 16, 2003
	076119 002	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 16, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-385	FEB 28, 2006
>ADD>	021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHL	4990517	JUN 30, 2009	U-298	I-385	FEB 28, 2006
			5607942	MAR 04, 2014	U-298		
			5849752	DEC 05, 2016	U-298		
>ADD>	021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	4990517	JUN 30, 2009		NDF	APR 15, 2006
>ADD>			5607942	MAR 04, 2014		PED	OCT 15, 2006
>ADD>			5849752	DEC 05, 2016			
>ADD>			4990517*PED	DEC 30, 2009			
>ADD>			5607942*PED	SEP 04, 2014			
>ADD>			5849752*PED	JUN 05, 2017			
	021330 001	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010			
	021330 002	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010			
	020845 002	NITRIC OXIDE;INOMAX	5873359	JAN 23, 2013	U-297		
	020845 003	NITRIC OXIDE;INOMAX	5873359	JAN 23, 2013	U-297		
	019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003		ODE	MAY 22, 2003
			4551456	NOV 14, 2003	U-80	PED	NOV 22, 2003
			4382892*PED	MAR 02, 2004			
			4551456*PED	MAY 14, 2004	U-80		
	021286 002	OLMESARTAN MEDOXOMIL;BENEVAS	5616599	APR 01, 2014	U-500		
	021286 001	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U-500		
	021286 003	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U-500		
	020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE	4695578	JAN 25, 2005			
			4753789	JUN 24, 2006	U-44		
	020776 001	OXAPROZIN POTASSIUM;DAYPRO ALTA	6030643	MAY 16, 2017	U-497		
	021106 001	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
			5849535	SEP 21, 2015			
			5958879	SEP 27, 2011	U-507		
			5350836	SEP 27, 2011	U-507		
			5681809	SEP 27, 2011	U-507		
	021106 002	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
			5849535	SEP 21, 2015			
			5958879	SEP 27, 2011	U-507		
			5350836	SEP 27, 2011	U-507		
			5681809	SEP 27, 2011	U-507		
	021106 003	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U-507	NCE	MAR 25, 2008
			5849535	SEP 21, 2015			
			5958879	SEP 27, 2011	U-507		
			5350836	SEP 27, 2011	U-507		
			5681809	SEP 27, 2011	U-507		
	020629 001	PENCICLOVIR SODIUM;DENAVIR	6469015	OCT 22, 2019	U-501		
	076061 001	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
	076061 002	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
	076061 003	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
	021438 001	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021438 002	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
	020903 001	RIBAVIRIN;REBETOL	6524570	NOV 01, 2016	U-499		
			6524570*PED	MAY 01, 2017	U-499		
>ADD>	021444 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
>ADD>	021444 002	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
>ADD>	021444 003	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
	019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4562829	MAY 01, 2004	U-503		
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-261	FEB 07, 2006
	020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
	021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 13, 2013			
>ADD>	019766 001	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
>ADD>	019766 002	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
>ADD>	019766 003	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
>ADD>	019766 004	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
>ADD>	019766 005	SIMVASTATIN;ZOCOR				I-390	APR 16, 2006
>ADD>	021083 001	SIROLIMUS;RAPAMUNE				I-386	APR 11, 2006
>ADD>	021110 001	SIROLIMUS;RAPAMUNE				I-386	APR 11, 2006
>ADD>	021110 002	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
>ADD>			5212155	MAY 18, 2010	U-291	I-386	APR 11, 2006
>ADD>			5308847	MAY 03, 2011	U-292		
>ADD>			5403833	APR 04, 2012	U-293		
>ADD>			5989591	MAR 11, 2018			
	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN				ODE	OCT 31, 2004
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
>ADD>	021148 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
>ADD>			5849700	DEC 15, 2015	U-340		
>ADD>			5849704	DEC 15, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021148 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
>ADD>			5849700	DEC 15, 2015	U-340		
>ADD>			5849704	DEC 15, 2015			
>ADD>	021148 003	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
>ADD>			5849700	DEC 15, 2015	U-340		
>ADD>			5849704	DEC 15, 2015			
>ADD>	021151 005	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
>ADD>						PED	AUG 22, 2003
>ADD>	020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			
>ADD>			4978655*PED	DEC 24, 2008			
>ADD>	021453 001	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U-248		
>ADD>			4978655*PED	DEC 24, 2008	U-248		
>ADD>	021453 002	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U-248		
>ADD>			4978655*PED	DEC 24, 2008	U-248		
>ADD>	021453 003	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U-248		
>ADD>			4978655*PED	DEC 24, 2008	U-248		
>ADD>	021453 004	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U-248		
>ADD>			4978655*PED	DEC 24, 2008	U-248		
	020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	6121314	MAY 18, 2012	U-502		
	021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	6121314	MAY 18, 2012	U-504		
	020489 001	TESTOSTERONE;ANDRODERM	4863970	NOV 14, 2006			
			4983395	NOV 12, 2007			
			5152997	DEC 11, 2010	U-490		
			5164190	DEC 11, 2010			
			4849224	NOV 12, 2007			
			4855294	SEP 06, 2008			
	020489 002	TESTOSTERONE;ANDRODERM	4849224	NOV 12, 2007			
			4855294	SEP 06, 2008			
			4863970	NOV 14, 2006			
			4983395	NOV 12, 2007			
			5152997	DEC 11, 2010	U-490		
			5164190	DEC 11, 2010			
	021454 001	TESTOSTERONE;TESTIM				NP	OCT 31, 2005
>ADD>	020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
>ADD>	020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
>ADD>	020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
>ADD>	020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
>ADD>	020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
>ADD>	020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004			
>ADD>	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004			
>ADD>	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004			
	021257 001	TRAVOPROST;TRAVATAN				M-23	FEB 13, 2006
	021108 001	TRETINOIN;RENOVA	6531141	MAR 07, 2020			
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-381	SEP 09, 2005
>ADD>						I-389	APR 01, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-381	SEP 09, 2005
>ADD>						I-389	APR 01, 2006
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-261	FEB 11, 2006
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-261	FEB 11, 2006
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-261	FEB 11, 2006
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-261	FEB 11, 2006
	020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	SEP 16, 2003			
			6146662	AUG 14, 2007	U-366		
	020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	SEP 16, 2003			
			6146662	AUG 14, 2007	U-366		

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 23RD EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

EXCLUSIVITY DOSING SCHEDULE

D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS

EXCLUSIVITY INDICATION

I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR

I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER

I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION

I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY

I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE

I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION

I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE

I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

I-389 SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS

I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....

EXCLUSIVITY MISCELLANEOUS

M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT

PATENT USE

U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

U-495 PERITONEAL DIALYSIS SOLUTION

U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE

U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST

U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION

U-500 USE AS AN ANTIHYPERTENSIVE AGENT

U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

U-502 PITYRIASIS VERSICOLOR

U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR

U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS

U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS

United States Government
INFORMATION
PUBLICATIONS ★ PERIODICALS ★ ELECTRONIC PRODUCTS

Approved Drug Products, ADP
SUBSCRIPTION ORDER FORM

Order Processing
Code: **8392**

Easy Secure Internet:
bookstore.gpo.gov

Toll Free: 866 512–1800
Phone: 202 512–1800
Fax: 202 512–2250

Mail: Superintendent of Documents
PO Box 371954
Pittsburgh, PA 15250–7954

❑ **YES,** enter my subscription(s) as follows:

_____subscription(s) of the ***Approved Drug products with Therapeutic Equivalence Evaluations, ADP,*** and the monthly Cumulative Supplements, for $108.00 per year. The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.

Personal name (Please type or print)

Company name

Street address City, State, Zip code

Daytime phone including area code

Purchase Order Number

Check method of payment:

❑ Check payable to Superintendent of Documents

❑ SOD Deposit Account ☐☐☐☐☐☐☐ – ☐

❑ VISA ❑ MasterCard ❑ Discover/NOVUS ❑ American Express

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

☐☐☐☐ (expiration date)

Thank you for your order!

Authorizing signature

02/03